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 Kinases play a crucial role in a variety of cell signaling pathways that control processes 
such as: growth, motility, and angiogenesis. Not surprisingly, dysregulation of proper kinase 
signaling often leads to cancer. Since the introduction of imatinib, a small molecule kinase 
inhibitor for the treatment of chronic myelogenous leukemia (CML), kinase inhibitors have 
become a popular drug class with 28 approved as drugs. All of these inhibitors bind in the 
conserved ATP-binding pocket, and as a result, many are promiscuous and bind off-target 
kinases. This dissertation describes our work to target kinases through mechanisms other than the 
ATP-binding pocket. Through targeting pockets other than the ATP-binding pocket, we also 
demonstrate the importance of understanding kinase global conformation.  
 We created bivalent inhibitors (inhibitors that can bind two sites within their target 
simultaneously) for two protein tyrosine kinases: c-Src and c-Abl. In both, the bivalent inhibitors 
were synthesized by linking an ATP-competitive inhibitor to an allosteric inhibitor of the kinase 
using azide-alkyne click chemistry. In doing so, we created inhibitors that were both more potent 
and selective than the separate binding pieces alone. Our c-Src bivalent inhibitor was the first c-
Src inhibitor that was selective for the active form of the kinase over the inactive form. 
Additionally, the bivalent inhibitor of c-Abl was cell permeable and had a cellular therapeutic 
index of 14. 
 We also discovered an allosteric modulator of c-Src via a screen of 1,000 compounds. 
We determined that this small molecule stabilizes the open conformation of c-Src and, 
accordingly, is an activator of c-Src. Finally, we investigated the interplay between an allosteric 
inhibitor of c-Abl (GNF-2) and various ATP-competitive inhibitors. None of the FDA approved, 
ATP-competitive inhibitors tested showed synergy with GNF-2 because they stabilized different 
global conformations in c-Abl. Only one ATP-competitive inhibitor stabilized the same 
conformation as GNF-2, and gratifyingly, this was the only combination that showed synergy. 
Additionally, this combination was capable of overcoming an imatinib resistant mutant in CML. 
These findings will play a crucial role in understanding drug combinations. This dissertation 
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Exploiting Small Molecules that Bind Outside the ATP-Pocket of Protein Tyrosine Kinases  
 
Abstract 
 Kinases are a highly abundant and important protein in cells. Within the last 15 years, 
kinase inhibitors have become important drugs. Due to the conserved nature of the ATP-binding 
pocket and the fact that most kinase inhibitors bind in this pocket, they are often promiscuous 
and are not always the best tools to study kinases in the cell. As complex, regulator enzymes, 
however, kinases often have other less conserved pockets that can be exploited to create selective 
inhibitors and learn more about the roles these important enzymes play in cellular signaling. The 
work introduced here describes several attempts to design and use small molecules that bind 
outside the ATP-binding pocket to study protein tyrosine kinases. 
 
Kinases Play an Important Role in Cell Signaling 
 Cellular processes are regulated by complex signaling pathways where protein kinases 
often play important regulatory roles. There are 518 known human protein kinases that make up 
almost 2% of the entire human genome (referred to as the kinome).
1
 Protein kinases transfer the 
gamma phosphate of ATP to a hydroxyl containing amino acid (serine, threonine, or tyrosine) on 
their protein substrate. It is estimated that about one-third of proteins are phosphorylated by 
kinases providing as many as 20,000 unique phosphoproteins.
2
 These phosphoproteins, in turn, 
propagate a cellular signal.
3
 This can be achieved in a variety of ways: the phosphorylation event 
can activate the protein substrate,
4
 inactivate the protein substrate,
5
 or provide a docking site for 
other signaling molecules.
6
 These signaling cascades control complex cellular processes such as: 
metabolism, transcription, cell cycle progression, motility, apoptosis, and differentiation.
1
 Not 
surprisingly, dysregulation of the kinase signaling involved in these processes often leads to 
disease states such as cancer.
7,8





 Despite the breadth and diversity of the kinome, there are many conserved features within 
the catalytic, kinase domain (Figure 1.1). The kinase domain is composed of an N-lobe mostly 
made up of β-sheets and the C-lobe which is comprised primarily of α-helices.
10
 These two lobes 
are connected via a linker region referred to as the hinge. ATP binds in the pocket formed at the 
interface of these two lobes. Furthermore, there are several features within this pocket that are 
necessary for transfer of the gamma phosphate on ATP to the hydroxyl containing amino acid 
substrate. 
i. A magnesium cofactor and the three conserved catalytic residues: Lys, Asp, and Glu. 
ii. The glycine-rich loop that forms the ceiling of the ATP binding site. It is often termed 
the phosphate-binding loop (P-loop) due to the role it plays in enabling catalysis by 
clamping down on the phosphates of ATP.
11
 
iii. The activation loop, containing the catalytic Asp, as well as a hydroxyl containing 





Figure 1.1. Conserved features of the kinase domain (PDB: 1Y57). The N-lobe is colored green and the C-lobe is 
colored gray with the hinge connecting the two highlighted in orange. The conserved catalytic residues are shown in 
stick form (red). The P-loop is highlighted in magenta and the activation loop in cyan with the phosphorylated 
tyrosine shown in stick form. 
3 
  
The Importance of Kinase Inhibitors 
 As early as the 1960s, with the discovery of a shortened chromosome, termed the 
Philadelphia chromosome, present in some leukemias,
12
 scientists have slowly been gaining 
information that there are specific molecular causes to some cancers. As such, targeted therapy 
that eliminates the molecular cause, and subsequently the cancer, has become the desired path for 
cancer treatment. In 2001, imatinib (Figure 1.2) became one of the first approved small 
molecule targeted therapies. The first two examples of specific targeted therapies before imatinib 
were both antibodies: rituximab for B-cell non-Hodgkin lymphoma and trastuzumab for HER2-
positive breast cancer.
13,14
 Imatinib treats chronic myelogenous leukemia (CML), which is 
caused by the aforementioned shortened, Philadelphia chromosome. CML is an adult leukemia 
that makes up approximately 15 to 20 percent of all adult leukemias.
15
 The Philadelphia 
chromosome is caused by the translocation of chromosomes 9 and 22 creating a fusion protein 
BCR-Abl between a portion of Abl1 on chromosome 9 and Bcr on chromosome 22.
16
 The fusion 
protein BCR-Abl causes cancer through several mechanisms. Firstly, the point of fusion between 
BCR and Abl cuts off the regulatory tail of Abl, which leads to a constitutively active Abl and 
aberrant Abl signaling.
17
 Additionally, BCR has a coiled-coil domain, which promotes 





Figure 1.2. Structure of imatinib 
 
 Imatinib is an ATP-competitive inhibitor of the kinase c-Abl. It was highly successful in 
CML treatment. Before the development of imatinib treatment, the median survival time for a 
patient with CML was 3-5 years. Now with imatinib treatment, the 7-10 year survival rate is 
approximately 85 percent.
15,18,19
 c-Abl is not the only kinase that imatinib inhibits; another target 
of imatinib is the kinase c-KIT. 
20
 Hirota et al. discovered in the late 1990s that c-KIT contains 
several gain-of-function mutations in gastrointestinal stromal tumors (GIST).
21
 Imatinib was then 
re-purposed successfully as a treatment for GIST.
20
 Due to the success of imatinib, more kinase-
4 
targeted therapies have emerged. There are now 28 approved kinase inhibitors.
22
 Of the 28 
approved kinase inhibitors, only four are specific for serine/threonine kinases. Almost all of 
these drugs target protein tyrosine kinases (PTKs). For this reason, the work in this dissertation 
focuses on two tyrosine kinases, c-Src and c-Abl. 
 The importance of c-Abl in cancer has already been described. c-Src is the other kinase 
studied in this dissertation due to the important role it also plays in cancer. In healthy tissues, c-
Src regulates cell division, motility, adhesion, angiogenesis, and survival.
9,23
 Not surprisingly, c-
Src is often overexpressed in cancer; however, it is increased c-Src activity, not overexpression, 
that most often correlates with malignant potential.
9,23
 Furthermore, c-Src contributes to 
trastuzumab (mentioned earlier) resistance in Her2-postitive breast cancer.
24
 Some of the cancers 
in which c-Src is implicated include colon, lung, and breast.
25
 Recent work from our lab has 
developed an inhibitor of c-Src that has been effective at shrinking triple negative breast cancer 
(TNBC) tumors in mice.
26
 TNBC is more difficult to treat than other breast cancers and could 
really benefit from a targeted therapy.
27,28
 
  All FDA approved kinase inhibitors bind to one of three unique conformations within the 
ATP-binding pocket.
22,29,30
 Most of these inhibitors (19 of 30) are classified as Type I inhibitors 
meaning that they bind the active kinase conformation. The active conformation is the 
conformation that binds ATP and is shown in Figure 1.1. Seven approved inhibitors are known 
as Type II inhibitors, and they bind the inactive, DFG-out conformation. The DFG-out 
conformation is characterized by an outward flip of the activation loop causing the catalytically 
important residues Asp-Phe-Gly (DFG) to flip out of the ATP-binding pocket.
31
 The third ATP-
binding pocket conformation is an addition inactive conformation referred to as αC-helix-out. 
This conformation is characterized by outward movement of the αC-helix which disrupts a salt 
bridge between the catalytic lysine and glutamate.
32,33
 Four ATP-competitive inhibitors are 
known to bind this conformation. Imatinib is relatively selective for c-Abl and binds the DFG-
out conformation of c-Abl. It was hypothesized that the selectivity of imatinib was due to the 
inability of most kinases to adopt the DFG-out. It was previously thought that c-Src could not 
adopt DFG-out; however, this has since been shown to be incorrect.
34,35
 Recently, using a 
"matched set" of conformation-selective kinase inhibitors, our lab has shown that DFG-out 






c-Src and c-Abl are Multi-Domain Kinases 
 All FDA-approved kinase inhibitors bind the ATP pocket.
37
 This is not surprising due to 
the fact that the ATP binding pocket is well-defined, hydrophobic pocket.
37
 Often, these 
compounds lack specificity due to the highly conserved nature of the ATP binding pocket. 
Furthermore, high cellular levels of ATP greatly diminishes the cellular potency of kinase 
inhibitors in vitro.
37
 There are several strategies for creating more selective kinase inhibitors. 
Most of these strategies involve interacting with elements outside the ATP-binding pocket.
38,39
 In 
order to bind regions outside the ATP-pocket, it is important to consider the global conformation 
of a kinase.  
 Earlier, we highlighted the conserved features of the kinase domain (Figure 1.1). Almost 
all kinases, including the PTKs c-Src and c-Abl, however, have other domains important for 
protein-protein interactions and autoregulation. The conformation that all the domains adopt in 
relation to each other is referred to as the global conformation. The global conformation of c-Src 
is shown in Figure 1.3. Both c-Src and c-Abl contain Src Homology 2 (SH2) and Src Homology 
3 (SH3) domains in addition to the catalytic, kinase domain. SH2 domains are small, 100 residue 
domains that recognize and bind phosphotyrosine residues.
40
 SH3 domains bind proline-rich 
sequences that form a polyproline type II helix.
40
 The SH2 and SH3 domains provide substrate 
docking sites and autoregulation for both kinases.
41,32,42
 Most commercial assays or kinase 
inhibitor studies only use the kinase domain;
43–45
 however, it is now known that inhibitors that 
bind within the ATP-binding pocket can cause global changes to the kinase.
33
 Described below 
are several methods for binding outside the ATP-binding pocket and interacting with the global 




Figure 1.3. Three domain structure of the PTK c-Src. The kinase (catalytic) domain is colored in green with the 
SH3 domain in magenta and the SH2 domain in cyan. An analog of ATP is shown in white in the ATP-binding 
pocket. 
 
Allosteric Kinase Modulators 
 Allosteric modulators bind in a site other than the active-site but have an impact upon the 
activity of the enzyme. Allosteric modulators are often unique to a particular kinase because they 
generally exploit more unique pockets within the kinase.
46
 For this reason, however, they are 
often more difficult to identify. There are several well studied allosteric inhibitors in Ser/Thr 
kinases. For example, the allosteric kinase inhibitor CI-1040 (Figure 1.4) inhibits the Ser/Thr 
kinases MEK1 and MEK2 by occupying a pocket adjacent to the ATP binding site.
47,48
 The 
Ser/Thr kinase Akt also has several allosteric inhibitors (Figure 1.4). These allosteric inhibitors 
of Akt only bind to the full length construct of Akt and not the kinase domain due to the unique 
mechanism of activation of Akt.
49
 These allosteric inhibitors of Akt demonstrate the importance 
of kinase global conformation and not just kinase catalytic activity. 
 In tyrosine kinases, one of the best examples of an allosteric inhibitor is GNF-2. GNF-2 
is a small molecule that binds in the myristate pocket of c-Abl (Figure 1.4).
50
 This pocket in c-
Abl provides a docking site for the autoregulatory myristate tail of c-Abl. This method of 
autoregulation in c-Abl is unique rendering GNF-2 highly selective.
42
 Furthermore, GNF-2 only 
demonstrates inhibitory effect with constructs of c-Abl that contain the SH2 and SH3 domains 
despite the fact that the myristate pocket resides in the kinase domain.
51
 Like many of the other 
allosteric inhibitors discussed, the binding of GNF-2 depends on the global structure of c-Abl. 
7 
This dissertation focuses on the PTKs c-Src and c-Abl, and since c-Abl already has a well 
established allosteric pocket, we wanted to focus on allosteric modulators of c-Src. Chapter III 
details our efforts to identify an allosteric inhibitor of c-Src that would modulate its global 
conformation. There are no examples of a allosteric inhibitors of c-Src; however, there is an 





Figure 1.4. Examples of allosteric inhibitors of protein kinases. 
 
Bivalent Kinase Inhibitors 
 Bivalent inhibitors are inhibitors capable of binding two sites of a protein simultaneously. 
This leads to a significant increase in potency due to the addition of the free energy of binding.
53
 
Furthermore, due to the ability to bind two unique sites, bivalent inhibitors have the potential to 
be highly selective. While the ATP-binding pocket of kinases is highly conserved, other pockets 
in kinases are more specialized to the unique substrates and function of a kinase.
52
 As such, a 
bivalent inhibitor that exploits these other binding sites has the potential for selectivity. There 
have been many examples of bivalent kinase inhibitors. Generally, these bivalent inhibitors can 
be broken into two classes: bisubstrate and generic bivalent inhibitors.
54
 Bisubstrate kinase 
inhibitors gain their name due to the fact that they bind in the binding pockets of both substrates 
of the kinase, ATP and the peptide/protein substrate. There are several examples in the literature 
as well as several that our lab has developed (Figure 1.5a).
54–56
 
 Generic bivalent inhibitors do not have as specific binding sites as bisubstrate inhibitors. 
Chapters II and IV detail our efforts to develop bivalent inhibitors for c-Src and c-Abl, 
respectively. There are already several accounts of bivalent inhibitors for these PTKs. In the 
early 2000s, Lawrence and coworkers developed a series of bivalent inhibitors of c-Src that 
linked an SH2 domain peptide to a substrate-binding peptide.
57–59
 Additionally, Maly and 




alkylguanine-DNA alkyltransferase (AGT) linker expressed in cells (Figure 1.5b).
60,61
 
Furthermore, our lab has developed bivalent inhibitors of c-Src using enzyme-templated 
fragment elaboration.
62
 With the work in Chapters II and IV, we hoped to improve upon the 
current bivalent inhibitors of c-Src and c-Abl by creating inhibitors that were specific to distinct 
global conformations of the kinase. The bivalent inhibitor of c-Abl utilizes and ATP-competitive 








Figure 1.5. Examples of (a) bisubstrate and (b) generic bivalent inhibitors of protein kinases. 
 
 As mentioned earlier, SH2 domains bind phosphotyrosine (pY) containing peptide 
sequences. Of the 32 non-receptor tyrosine kinases, most of which contain an SH2 domain, most 
are specific for the peptide sequences that they bind.
63
 The Src family kinases (c-Src, Hck, Yes, 
Fyn, Lyn, Blk, Yrk, Fgr, and Lck)
25
 all bind an optimal sequence of pYEEI
64
 while c-Abl binds 
an optimal sequence of pYENP.
65
 The peptide specificity results from the amino acids three 
residues c-terminal to the phosphotyrosine.
65
 There has been some work to develop small 
molecules that bind SH2 domains.
66
 There are several reported small molecules that bind the 
SH2 domain of c-Src.
67,68
 Furthermore, by replacing the phosphotyrosine with 4′-
(difluorophosphonomethyl)phenylalanine (F2Pmp), it was possible to create phosphatase-




Drug Combination Therapy 
 Before the early 1960s, the idea of combining chemotherapy drugs seemed unthinkable, 
but now it is considered the standard treatment. One of the first combination therapies for cancer 
was "VAMP" used for child leukemias.
69
 "VAMP" was an acronym for the combination of 
vincristine, amethopterin, 6-mercaptopurine, and prednisone, and it was the first of many 
9 
combination treatment programs that drastically increased the rate and duration of remission.
69
 
After VAMP, combination therapy boomed with the creation of MOMP which combined 
nitrogen mustard, vincristine, methotrexate, and prednisone for Hodgkins lymphoma and 
cyclophosphamide, methotrexate, and 5-fluorouracil for breast cancer.
69
 Combination therapies 
are successful because they can target different pathways involved in the cancer. Additionally, 
combining drugs can lower the dose of drug required to achieve an effect, which then can lower 
the negative side effects. Furthermore, drug combinations can sometimes work together to create 
an even better effect than one would expect from a simple addition of two agents, a phenomenon 
referred to as synergy.
70
 Synergistic combinations can further lessen the negative side effects by 
requiring even less drug. 
 Combination therapy can also be used with kinase inhibitors. Generally, kinase inhibitor 
combinations involve kinase inhibitors that target different pathways; however, it could be 
feasible to target a single kinase with combinations of allosteric and ATP-competitive inhibitors. 
As mentioned earlier, allosteric modulators of kinases are excellent tools. Furthermore, since 
they bind in sites distinct from the conserved ATP-binding pocket, one could imagine that 
combining allosteric with ATP-competitive inhibitors could have far reaching implications for 
the treatment of kinase driven diseases. Already, there have been results that show combining 
allosteric and ATP-competitive inhibitors can overcome clinical resistance mutations. Gray and 
coworkers demonstrated that GNF-2 can be combined with nilotinib (an approved c-Abl 
inhibitor for CML) to overcome a clinical mutation that neither inhibitor can target (T315I).
71
 In 
fact, Novartis is currently developing GNF-2 analogs for combination therapy with Nilotinib to 
treat the T315I mutation.
72
 Our research described in Chapter V, further investigates 
combinations of ATP-competitive inhibitors and GNF-2. 
 
Conclusions 
 Kinases play an important role in regulating a variety of cellular processes. When these 
pathways are dysregulated, they often lead to disease states such as cancer. Targeted therapies 
such as kinase inhibitors have proven successful drugs. They are also important probes to 
continue to study kinase function in cells. Unfortunately, all approved kinase inhibitors bind in 
the conserved ATP-binding pocket, which causes some of them to be promiscuous and bind off-
target kinases. To establish selective and valuable tools to study kinases biochemically and 
10 
incellulo, we looked to create and utilize inhibitors that bind outside the conserved ATP-binding 
pocket. We used several different strategies that all yielded a wealth of information about kinase 
global conformation and biology. 
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Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domaina 
 
Abstract 
 We have developed a general methodology to produce bivalent kinase inhibitors for c-Src 
that interact with the SH2 and ATP binding pockets. Our approach led to a highly selective 
bivalent inhibitor of c-Src. We demonstrate impressive selectivity for c-Src over homologous 
kinases. Exploration of the unexpected high level of selectivity yielded insight into the inherent 
flexibility of homologous kinases. Finally, we demonstrate that our methodology is modular and 
both the ATP-competitive fragment and conjugation chemistry can be swapped. 
 
Introduction 
 Protein kinases are key regulatory enzymes in human cell signaling, both in healthy and 
diseased tissue. Efforts to pharmacologically elucidate kinase signaling have been hampered by a 
lack of selective kinase inhibitors.
1–3
 The vast majority of reported kinase inhibitors bind to the 
conserved ATP-site.
4
 Owing to the conserved nature of the ATP pocket, nearly all ATP-
competitive kinase inhibitors are promiscuous and bind to undesired off-targets.
4–6
 One strategy 




 We previously reported bisubstrate inhibitors of c-Src in which an ATP-competitive 
inhibitor was tethered to a substrate phosphorylation site peptide.
10
 Here, we explore the 
conversion of a promiscuous ATP-competitive kinase inhibitor into a bivalent inhibitor of c-Src 
that interacts with the SH2 domain of c-Src (in addition to the ATP-binding pocket). Our strategy 
involves conjugation of the two binding elements with “click chemistry” to enable a modular 
                                                          
a
 The work in this chapter contains a few small additions to the published work presented in Johnson, T. K.; 
Soellner, M. B. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain. Bioconjug. Chem. 




  We demonstrate that both copper-catalyzed and catalyst-free strain-release click 
reactions
12
 can readily be employed to construct bivalent inhibitors. The modularity of our 
design is showcased by the synthesis of two distinct bivalent inhibitors starting from two 
different ATP-competitive inhibitor fragments. 
 Bivalent kinase inhibitors that target two distinct domains have been reported,
8,9
 
however, there are no reports of such bivalent inhibitors purely constructed of small molecule—
peptide hybrids. In addition, little is known about the selectivity changes transitioning from a 
promiscuous ATP-competitive inhibitor to a bivalent inhibitor also targeting a regulatory domain 
(here SH2 domain).
13
 Lawrence and co-workers reported fully peptidic bivalent inhibitors that 
link a substrate-phosphorylation site peptide to a SH2 domain interacting peptide.
14,15
 Maly and 
co-workers have reported linking ATP-competitive small molecules to SH2 domain binding 
peptides using a large, protein-based linker.
16
 In contrast, our design provides a significantly 
lower molecular weight bivalent inhibitor than either method previously described. 
 
Figure 2.1. Conformational equilibrium of c-Src. c-Src exists in equilibrium between “open” and “closed” 
conformations. The closed, autoinhibited conformation (left, PDB: 2SRC), and open, active conformations (middle, 
PDB: 1Y57, and right, PDB: 1OPL). The kinase catalytic domains are colored green, SH2 domains colored blue, 
and SH3 domains colored red. For each conformation, distances between the ATP-binding pocket and the SH2 
phosphotyrosine binding pockets are displayed and colored gold. 
 
 c-Src is known to exist in two distinct global conformations, open and closed (Figure 
1.1).
17,18
 The open conformation is the conformation that exists associated with the plasma 
membrane and is known to correlate with disease progression.
19
 In contrast to the open 
conformation, the closed conformation is highly rigid.
20
 Crystal structures of the closed 
conformation reveal that the distance between the ATP-pocket and the phospho-Tyr binding 
pocket of the SH2 domain is 37 Å (Figure 1.1 and Appendix A, Figure A.1) Due to the inherent 
17 
rigidity of the inactive conformation, we hypothesized that we could selectively inhibit the open 
conformation using a bivalent inhibitor constructed with a linker shorter than 37 Å. We predicted 
that a bivalent inhibitor with a linker too short to interact with the closed, rigid conformation 
could still bind to the open, flexible conformation. To our knowledge, there has been no report of 
a c-Src inhibitor that can selectively inhibit the active conformation over the inactive 
conformation. 
 
Bivalent Inhibitor Design 
 Our design strategy involves ATP-competitive inhibitors with a pendant alkyne and a 
SH2 domain binding phospho-peptide containing a PEG linker and pendant azide (Scheme 
2.1).
21,22
 We hypothesized that a linker shorter than 37 Å could provide an inhibitor that 
selectively inhibits the active conformation of c-Src. Thus, we elected to use a 33-atom PEG 
linker with a calculated maximal length of 25 Å (Appendix A, Figure A.2). For an ATP-
competitive inhibitor, we selected an aminopyrazole fragment that is a promiscuous kinase 
inhibitor.
23
 We previously profiled an aminopyrazole fragment and found that it potently binds 
117 of 200 kinases in that panel.
24
 To enable conjugation to a peptide, we synthesized 2.1, an 
aminopyrazole fragment with a pendant alkyne. We found 2.1 to be a competent inhibitor of 3-
domain c-Src (IC50 = 2.9 µM). For the SH2 domain interacting peptide, we selected a previously 
reported pentapeptide, H2N-Q-pY-E-E-I-CONH2.
25
 Solid phase peptide synthesis was employed 
to synthesize 2.2, the SH2 interacting peptide with an N-terminal azido linker.
26
 Copper-




Biochemical Evaluation of Bivalent Inhibitor  
 We evaluated bivalent inhibitor 2.3 in a continuous activity assay
27
 with 3-domain c-Src
28
 
and found 2.3 was a potent inhibitor (Table 2.1, IC50 = 0.16 µM). Relative to ATP-competitive 
fragment 2.1, this represents a 18-fold improvement in binding affinity. We next tested 2.3 
against a kinase domain only construct of c-Src and found that bivalent inhibitor 2.3 has similar 
affinity to the ATP-competitive inhibitor alone (2.3, IC50 = 2.1 µM; 2.1, IC50 = 1.3 µM). These 
results are consistent with bivalent inhibitor 2.3 requiring both the catalytic and SH2 domains to 
achieve optimal binding. Comparing kinase domain to 3-domain c-Src constructs, bivalent 
inhibitor 2.3 binds 13-fold tighter to the c-Src construct with an SH2 domain (Table 2.1). 
  
 
Scheme 2.1. Copper catalyzed click cycloaddition of ATP-competitive alkyne 2.1 and azido-SH2-peptide 2.2 afford 











kinase domain 1.3 ± 0.5 2.1 ± 0.3 
3-domain (3D) 2.9 ± 0.6 0.16 ± 0.01 
pY416 3D 2.4 ± 0.6 0.24 ± 0.1 
pY527 3D 1.4 ± 0.1 1.8 ± 0.1 
SH2-eng 3D 2.7 ± 0.6 2.2 ± 0.8 
 
 We hypothesized that using a linker shorter than the distance from the ATP-site to the 
SH2-domain found in the crystal structure for inactive/closed conformation of c-Src (PDB: 
2SRC) we could selectively target the more flexible active conformation of c-Src. To test this 
hypothesis, we utilized constructs of 3-domain c-Src that are active (pY416)
29
 and conformations 
known to be inactive and rigid (pY527 and SH2-engaged).
17,30
 Gratifyingly, we found that 
bivalent inhibitor 2.3 is a selective inhibitor of pY416 c-Src over the pY527 and SH2-engaged 
constructs (Table 2.1: pY416 IC50 = 0.24 µM, pY527 IC50 = 1.8 µM, SH2-engaged IC50 = 2.3 
µM). In contrast, ATP-competitive inhibitor 2.1 has no preference for open vs closed c-Src 
constructs (see Appendix A for additional data). To our knowledge, there are no reports for any 
kinase inhibitor with this level of selectivity for the active kinase conformation. 
 






Hck 8.9 2.8 ± 0.7 
Lck 9.3 5.3 ± 0.6 
Blk 21.8 5.3 ± 0.7 
Frk 9.6 5.6 ± 0.4 
Fgr 4.6 3.1 ± 0.9 
Lyn 10.8 2.5 ± 0.2 
Abl 15.0 4.0 ± 0.4 
Fyn1 2.8 0.27 ± 0.02 
 
 Next, we wanted to determine whether bivalent inhibitor 2.3 is selective for c-Src over 
homologous kinases. Thus, we tested both ATP-competitive inhibitor 2.1 and bivalent inhibitor 
2.3 for inhibition against a panel of 8 homologous kinases,
31
 including 7 members of the Src 
family (Table 2.2). ATP-competitive inhibition 2.1 could only be tested with n=1 IC50 curves 




 The average IC50 for bivalent inhibitor 2.3 was 3.5 µM, with the exception of Fyn1. 
From these data, we observe that 2.3 is highly selective (average of 22-fold selective) for c-Src 
across this panel of homologous kinases. In addition, we observed only a modest increase in 
potency for bivalent inhibitor 2.3 compared to ATP-competitive inhibitor 2.1.  
The level of selectivity we observed across homologous kinases is very impressive, 
however, it was unexpected given that the ATP-competitive inhibitor inhibits each kinase 
similarly and the SH2 binding element is known to interact with many Src family kinases.
25,34
 
We wanted to study the surprising selectivity using c-Src and Hck kinases. The ATP-competitive 
fragment binds with similar potency to both c-Src and Hck (c-Src IC50 = 2.9 ± 0.6 µM; Hck IC50 
= 8.9 ± 0.5 µM) and cannot explain the selectivity observed for bivalent inhibitor 2.3. Next, to 
probe the affinity of the SH2 interacting peptide with both c-Src and Hck, we measured the 
affinity of a related SH2 peptide containing a N-terminal fluorophore and the same core residues 
as our bivalent inhibitor (FITC-E-P-Q-pY-E-E-I-P-I-Y-L-NH2, bold corresponds to the core 
SH2 binding residues found in bivalent inhibitor 2.3). We found the SH2 peptide binds to both c-
Src and Hck with equal affinity (c-Src EC50 = 0.72 ± 0.1 µM, Hck EC50 = 1.0 ± 0.3 µM). From 
these data, we conclude that the selectivity is not arising from either the ATP-competitive 
fragment or the SH2-binding element.  
We hypothesized that the inter-domain flexibility for homologous kinases might be 
different – and thus responsible for the selectivity observed. To explore this hypothesis, we 
measured the binding of our bivalent inhibitor 2.3 to 3-domain Hck constructs with varied 
open/closed (flexible/rigid) conformations (in order of most open and flexible to most closed and 
rigid: wild-type, SH2-engaged, and SH3-engaged).
35,36
 We found that bivalent inhibitor 2.3 binds 
tighter to SH3-engaged compared to wild-type 3-domain Hck (IC50 = 0.6 and 2.8 µM, 
respectively). These data suggest that activated Hck is less flexible than c-Src. Furthermore, 
engagement of the SH3 domain of Hck likely brings the SH2 and catalytic domains closer in 
proximity. Interestingly, Fyn1 is the only Src family kinase (SFK) other than c-Src for which 3 
binds potently (Fyn1 IC50 = 0.27 µM). A recent study of SFKs indicated that Fyn1 was 
significantly more flexible than other SFKs.
37
 Together, our findings reveal that homologous 
kinases have varied conformational flexibility, and that this flexibility can be selectively targeted 
using bivalent kinase inhibitors. 
21 
 We have previously shown that bisubstrate kinase inhibitors are less susceptible to 
mutations within a single binding pocket.
10
 We wanted to determine whether bivalent inhibitor 
2.3 could inhibit c-Src with a clinically relevant gatekeeper mutation (T338M).
38
 The T338M 
mutation renders c-Src resistant to nearly all ATP-competitive inhibitors, including all FDA-
approved inhibitors of c-Src.
39,40
 We found that bivalent inhibitor 2.3 is also potent inhibitor of 
3-domain T338M c-Src (IC50 = 0.19 µM). These data suggest that bivalent inhibition of kinases 




Figure 2.2. Copper catalyzed dasatinib bivalent 2.4 and catalyst-free bivalent 2.5. 
 
Modular Design 
 Our conjugation strategy, utilizing azide-alkyne click chemistry, was designed to be 
modular in nature. To showcase the modularity, we synthesized an analog of dasatinib (an FDA-
approved dual c-Src/Abl inhibitor) with a pendant alkyne (see Materials and Methods for 
details).
41
 Conjugation to the azido SH2 peptide 2.2 to dasatinib~alkyne (2.15) yielded bivalent 




assays (due to titration of the lowest enzyme concentrations accessible to our activity assay). 
Thus, we utilized a commercial binding assay that is performed in reticulocyte lysate containing 
~5 mM ATP (Luceome Biotechnologies, Tucson, AZ)
42,43
 to measure the affinity of 2.4 with 
full-length c-Src. In this assay, compound 2.4 has an IC50 = 1 nM for full length Src, while the 
ATP-competitive fragment (dasatinib) has an IC50 of 18 nM. This represents an 18-fold 
improvement in binding affinity upon conversion of the ATP-competitive fragment to bivalent 
inhibitor 2.4. Notably, an 18-fold improvement is identical to the binding affinity increase found 
with the aminopyrazole-based system. These data demonstrate that the ATP-competitive 
inhibitor can be swapped for a different ligand in a straightforward manner. Thus, one could 
modulate selectivity (or other properties) by selecting from a multitude of known ATP-
competitive kinase inhibitors. 
 Finally, we wanted to explore whether we could replace the copper-catalyzed click 
conjugation chemistry with a strain-release click chemistry. To enable catalyst-free conjugations, 
we synthesized dasatinib with a pendant cyclooctyne (Scheme 2.5). Incubation of azido peptide 
2.2 with dasatinib~cyclooctyne provided bivalent inhibitor 2.5 (Figure 2.2). In our enzymatic 
activity assay, this bivalent inhibitor titrates enzyme (Ki < 10 nM), having similar activity to the 
copper catalyzed version (2.4). One advantage of catalyst-free cycloadditions is the ability to 
perform on-enzyme conjugation in situations where copper might be toxic.
12,44
 This could enable 
rapid in situ generation of bivalent kinase inhibitors from starting fragments. 
 
Conclusions 
 We have developed a platform to generate bivalent inhibitors that interact both with the 
ATP-binding site and a regulatory domain, here a SH2 domain. While the ATP pocket is 
conserved across the kinome,
4
 interaction with a SH2 domain can provide instant selectivity 
because the vast majority of kinases do not possess a SH2 domain.
45
 Furthermore, we found that 
our ATP-to-SH2 bivalent kinase inhibitors possess high selectivity across homologous kinases. 
We found that selectivity can be obtained even for kinases which share optimal SH2-peptide 
binding sequences. Using model kinases with varied flexibility, we demonstrated that flexibility 
of the kinase (in particular inter-domain flexibility) is responsible for the high level of selectivity 
obtained. 
23 
 To demonstrate the modularity of our bivalent inhibitor design, we swapped the ATP-
competitive fragment to a dasatinib analog and obtained a bivalent inhibitor with single digit 
nanomolar potency. The conjugation chemistry can also be changed, here we used both copper-
catalyzed and strain-promoted click reactions to synthesize bivalent inhibitors.  
While outside the scope of this chapter, we have previously demonstrated that peptide-
based kinase inhibitors can be used in cellular assays after appending a cell-penetrating peptide.
10
 
In addition, one could envision using small molecule SH2 ligands to construct fully non-peptide 
bivalent inhibitors that might have inherent cell permeability.  These studies are ongoing in our 
laboratory. 
 
Materials and Methods 
 
General Synthetic Methods 
 Unless otherwise noted, all reagents were obtained via commercial sources and used 
without further purification. All 
1
H NMR spectra were measured with a Varian MR400 or Inova 
500 spectrometer. Mass Spectrometry (HRMS) was carried out by the University of Michigan 




Scheme 2.2: Synthetic Scheme for Compound 2.1 
 




Scheme 2.3: Synthetic Scheme for Compound 2.10 
 




Synthesis of 2.7: Compound 2.6 (997.4 mg, 8.10 mmol) was combined with 2,6-dichloro-4-
methylpyrimidine (1.3216 g, 8.11mmol) in an oven-dried round bottom flask. DMA (20.0 mL) 
was added followed by DIEA (2.10 mL, 12.02 mmol) and the reaction was stirred at 80°C 
overnight. The reaction was then brought up in EtOAc and washed 3 times with sat. NH4Cl. 
After drying over Na2SO4, the product was purified by silica gel chromatography using a Biotage 
Isolera One (linear gradient 40 → 90% EtOAc in hexanes). The pure fractions were combined 
and the solvent was removed under reduced pressure to yield 2.7 as a yellow solid (690 mg, 34% 
yield). Spectral data. 
1
H NMR (500 MHz, Chloroform-d) δ 9.82 (s, 1H), 7.50 (s, 1H), 7.08 (s, 
1H), 5.84 (s, 1H), 2.56 (s, 3H), 1.87 (tt, J = 8.4, 5.0 Hz, 1H), 1.04 – 0.99 (m, 2H), 0.76 (dt, J = 
6.6, 4.8 Hz, 2H); 
13
C NMR (100 MHz, dmso) δ 167.81, 160.80, 148.28, 146.32, 101.48, 92.70, 
25.69, 8.18, 7.13; HRMS-ESI (m/z): [M + H]
+
 calcd for C11H12ClN5 250.0854; found 250.0853. 
 




Synthesis of 2.9:  4-pentynoic acid (392.9 mg, 4.01 mmol) was added to an oven-dried flask. 
Anhydrous THF (2.70 mL) was then added to the flask followed by N-methylmorpholine (0.44 
mL, 4.03 mmol). Isobutyl chloroformate (0.52 mL, 4.03 mmol) was then added dropwise and the 
reaction was stirred for 30 minutes. The reaction was then filtered and washed with THF. The 
filtrate was then added to a solution of 2.8 (481.6 mg, 2.59 mmol) in anhydrous THF (2.7 mmol), 
and the reaction was stirred for 2 hrs. Upon completion, the solvent was removed under reduced 
pressure. The resulting residue was brought up in EtOAc and washed one time each with sat. 
bicarb, 10% citrate, and brine. After drying over Na2SO4, the product was purified by silica gel 
chromatography using a Biotage Isolera One (linear gradient 30 → 80% EtOAc in hexanes). The 
pure fractions were combined and the solvent was removed under reduced pressure to yield 2.9 
2.8 2.9 2.10 
25 
as a white solid (690 mg, 97% yield). Spectral data.
 1
H NMR (500 MHz, Chloroform-d) δ 3.60 
(t, J = 5.4 Hz, 2H), 3.43 (d, J = 22.3 Hz, 6H), 2.60 – 2.53 (m, 4H), 1.98 (q, J = 2.5 Hz, 1H), 1.47 
(s, 9H); 
13
C NMR (126 MHz, cdcl3) δ 188.00, 169.54, 83.30, 80.36, 68.87, 45.21, 41.51, 32.18, 
28.36, 14.49; HRMS-ESI (m/z): [M + H]
+
 calcd for C14H22N2O3 267.1703; found 267.1705, [M 
+ Na]
+
 calcd for C14H22N2O3 289.1523; found 289.1522.  
 
Synthesis of 2.10:  2.9 (266.2 mg, 0.98 mmol) was added to an oven-dried flask. Anhydrous 1,4-
dioxane (0.62 mL) was added followed by 4 N HCl in dioxane (2.30 mL, 9.2 mmol). The 
resulting solution was stirred for 1.5 hrs. The solvent was then removed under reduced pressure. 
The resulting residue was carried forward crude without purification assuming theoretical yield. 
 
Synthesis of 2.1:  2.10 (199.5 mg, 0.98 mmol) was added to an oven-dried flask. DCM (10.0 
mL) was added followed by TEA (0.15 mL, 1.08 mmol). The resulting mixture was stirred for 
0.5 hrs and then washed once with 10% K2CO3. The solvent was then removed under reduced 
pressure. 2.7 was added to the flask containing the resulting residue and brought up in EtOH (3.0 
mL). Concentrated HCl was added and the reaction was refluxed overnight. Upon completion, 
the EtOH was removed under reduced pressure. The resulting residue was brought up in EtOAc 
and washed 3 times each with bicarb and brine. After drying over Na2SO4, the product was 
purified by silica gel chromatography using a Biotage Isolera One (linear gradient 0 → 5% 
MeOH in EtOAc). The pure fractions were combined and the solvent was removed under 
reduced pressure to yield 2.1 as a white solid (100 mg, 54% yield). Spectral data.
 1
H NMR (500 
MHz, DMSO-d6) δ 12.02 (s, 1H), 9.26 (s, 1H), 6.55 (s, 1H), 5.76 (s, 1H), 3.54 (s, 8H), 2.77 (t, J 
= 2.6 Hz, 1H), 2.59 (t, J = 7.4 Hz, 2H), 2.38 (td, J = 7.5, 7.0, 2.6 Hz, 2H), 2.28 (s, 3H), 1.88 – 
1.80 (m, 1H), 0.89 (dt, J = 8.7, 3.2 Hz, 2H), 0.68 – 0.63 (m, 2H); 
13
C NMR (100 MHz, dmso) δ 
169.62, 165.13, 162.91, 92.01, 84.53, 81.54, 71.66, 44.53, 43.96, 43.68, 41.12, 31.75, 25.83, 
14.28, 8.18, 7.29; HRMS-ESI (m/z): [M + H]
+















Synthesis of 2.2:  Compound 2.2 was synthesized on 0.2 mmol scale on Rink Amide AM resin 
(0.47 mmol/g) using standard Fmoc solid-phase peptide synthesis. Couplings were performed 
using DIEA and HBTU in NMP and were allowed to proceed for 30 minutes at room 
temperature with the exception of 2.11, which was coupled using PyBOP. Fmoc deprotections 
were performed using piperidine in NMP and were allowed to proceed for 15 min at room 
temperature. The completeness of each coupling and deprotection was monitored by the Kaiser 
test. After deprotection of the final amino acid in the sequence, the peptide was capped by 
coupling on N3-PEG7-CO2H using PyBOP and DIEA in NMP. Cleavage of the peptide from the 
resin with concomitant removal of all side chain-protecting groups was accomplished with 2 mL 
of a 95% TFA, 2.5% H2O, and 2.5% TIPS solution for 45 minutes twice. The TFA was mostly 
removed under reduced pressure. The product was precipitated in ether and carried forward 




Synthesis of 2.12:  2.2 (135.2 mg, 0.1 mmol), CuI (19.1 mg, 0.1 mmol) and 2.1 (55.0 mg, 0.14 
mmol) were added to an oven-dried flask. DMF (1.0 mL) was added followed by TEA (0.05 mL, 
0.36 mmol). The reaction mixture was stirred at 60°C overnight. The reaction was purified by 
reverse-phase HPLC using a linear 5→95% acetonitrile + 0.1% TFA in water gradient. 
Lyophilization afforded 2.12 as a white solid (48.5 mg, 28% yield). Spectral data. MS-ESI 
(m/z): [M + 2H]
+




Synthesis of 2.3:  2.12 (48.5 mg, 0.028 mmol) was added to an oven-dried flask. DCM (0.5 mL) 
was then added followed by TMS-Br (0.5 mL) and the reaction mixture was stirred overnight. 
The solvent was then removed under reduced pressure. The reaction mixture was then suspended 
in water (0.5 mL) and stirred for 2 hrs. The reaction was purified by reverse-phase HPLC using a 
linear 5→95% acetonitrile + 0.1% TFA in water gradient. Lyophilization afforded 2.3 as a white 
powder (5.5 mg, 12% yield). Spectral data. HRMS-ESI (m/z): [M] calcd for C72H111N18O26P 




Scheme 2.4: Synthetic Scheme for Compound 2.15. 
 




Synthesis of 2.14: 2.13 (76.1 mg, 0.19 mmol) was added to an oven-dried flask. Anhydrous 
DMA (0.38 mL) was added followed by piperazine (112.8 mg, 0.95 mmol). The resulting 
solution was stirred at 80°C for 2.5 hrs. After completion, the reaction was cooled to room 
temperature and water was added to precipitate the product. The resulting residue was filtered 
and carried forward crude without purification. 
 
Synthesis of 2.15: (COCl)2 (0.02 mL, 0.23 mmol) was added to a stirred solution of 4-pentynoic 
acid (15.1 mg, 0.075 mmol) in anhydrous DCM (0.23 mL). Catalytic DMF (1 drop) was added 
and the reaction was allowed to stir for 2 hrs. The solvent was then removed under reduced 
pressure. The resulting residue was then dissolved in anhydrous THF (0.5 mL). 2.14 (41.8 mg, 
0.09 mmmol) and TEA (0.02 mL, 0.14 mmol) were added and the reaction was allowed to stir 
overnight. The solvent was then removed under reduced pressure. The resulting residue was 
brought up in EtOAc and washed with 10% citrate, sat. bicarb, and brine. After drying over 
Na2SO4, the product was purified by silica gel chromatography using a Biotage Isolera One 
(linear gradient 50 → 100% EtOAc in Hexanes). The peak fractions were combined and the 
solvent was removed under reduced pressure. The product was not pure and was further purified 
by reverse-phase HPLC using a linear 30→90% acetonitrile + 0.1% TFA in water gradient. 
Lyophilization afforded 2.15 as a white solid (3.2 mg, 8.1% yield). Spectral Data. 
1
H NMR 
(500 MHz, DMSO-d6) δ 11.53 (s, 1H), 9.89 (s, 1H), 8.22 (s, 1H), 7.40 (d, J = 7.7 Hz, 1H), 7.27 
(dt, J = 15.4, 7.5 Hz, 2H), 6.06 (s, 1H), 3.56 (d, J = 6.5 Hz, 8H), 2.78 (t, J = 2.7 Hz, 1H), 2.59 (t, 
J = 7.4 Hz, 2H), 2.42 (s, 3H), 2.38 (td, J = 7.5, 7.1, 2.6 Hz, 2H), 2.23 (s, 3H); 
13
C NMR (176 




129.46, 128.62, 127.44, 84.53, 83.21, 71.71, 44.48, 43.91, 43.66, 42.55, 31.82, 25.99, 18.74, 
14.30; HRMS-ESI (m/z): [M + H]
+




Synthesis of 2.16:  2.2 (20.3 mg, 0.015mmol), CuI (5.8 mg, 0.03 mmol) and 2.15 (6.3 mg, 0.012 
mmol) were added to an oven-dried flask. DMF (0.24 mL) was added followed by TEA (0.01 
mL, 0.07 mmol). The reaction mixture was stirred at 45°C overnight. The reaction was purified 
by reverse-phase HPLC using a linear 20→80% acetonitrile + 0.1% TFA in water gradient. 
Lyophilization afforded 2.16 as a white solid (4.0 mg, 18% yield). Spectral data. MS-ESI (m/z): 
[M + 2H]
+




Synthesis of 2.4:  2.16 (4.0 mg, 0.002 mmol) was added to an oven-dried flask. ACN (0.5 mL) 
was then added followed by TMS-Br (0.5 mL) and reaction mixture was stirred overnight. 
Water (0.5 mL) was then added and the reaction was again stirred overnight. The solvent was 
then removed under reduced pressure. The reaction was purified by reverse-phase HPLC using a 
linear 20→80% acetonitrile + 0.1% TFA in water gradient. Lyophilization afforded 2.4 as a 
30 
white powder (0.5 mg, 14% yield). Spectral data. HRMS-ESI (m/z): [M] calcd for 
C77H112ClN18O27PS 1818.7091; found after resolved isotope deconvolution 1818.7093. 
 
 
Scheme 2.5: Synthetic Scheme for Compound 2.18 
 
Synthesis of 2.17: 2.14 (95.2 mg, 0.21 mmol) was added to an oven-dried flask. Dioxane (1.0 
mL) was added followed by succinic anhydride (21.0 mg, 0.21 mmol). The resulting solution 
was stirred at 80°C overnight. After completion, the reaction was cooled to room temperature. 
The resulting residue was filtered to afford 2.17 as a tan solid (83.0 mg, 73% yield). Spectral 
Data. 
1
H NMR (500 MHz, DMSO-d6) δ 11.95 (s, 1H), 11.53 (s, 1H), 9.89 (s, 1H), 8.23 (s, 1H), 
7.40 (d, J = 7.6 Hz, 1H), 7.27 (dt, J = 15.3, 7.5 Hz, 2H), 6.06 (s, 1H). 3.56 (dd, J = 17.6, 11.5 Hz, 
8H), 2.58 (t, J = 6.6 Hz, 2H), 2.45 (t, J = 6.7 Hz, 2H), 2.42 (s, 3H), 2.24 (s, 3H). 
13
C NMR (100 
MHz, dmso) δ 174.36, 170.24, 165.62, 162.93, 162.63, 160.32, 157.37, 141.25, 139.24, 133.93, 
132.85, 129.45, 128.30, 127.43, 126.17, 83.17, 66.77, 44.39, 43.82, 43.62, 29.33, 27.92, 26.01, 
18.73. MS-ESI (m/z): [M + H]
+
 calcd for C24H26ClN7O4S 544.1528; found 544.1522. 
 
Synthesis of 2.18: 2.17 (49.0 mg, 0.09 mmmol) and HATU (45.5 mg, 0.12 mmol) were added to 
an oven-dried flask. DMF (0.92 mL) and TEA (0.04 mL, 0.28 mmol) were added and the 
reaction was allowed to stir for 10 min. After pre-activation of the acid, DBCO-amine (23.7 mg, 
0.09 mmol) was added and the reaction was stirred overnight. After completion, the reaction was 




2.18 as a tan solid (59.5 mg, 81% yield). Spectral Data. 
1
H NMR (700 MHz, DMSO-d6) δ 11.50 
(s, 1H), 9.87 (s, 1H), 8.22 (s, 1H), 7.67 (t, J=5.7 Hz, 1H), 7.61 (d, J=7.6 Hz, 1H), 7.60-7.55 (m, 
1H), 7.49-7.46 (m, 1H), 7.45-7.41 (m, 1H), 7.37 (td, J=7.6, 1.6 Hz, 2H), 7.33 (t, J = 7.5 Hz, 1H), 
7.29-7.25 (m, 2H), 7.23 (t, J = 7.7 Hz, 1H), 6.05 (s, 1H), 5.02 (d, J=14.0 Hz, 1H), 3.61 (d, J=14.0 
Hz, 1H), 3.58-3.44 (m, 9H), 3.12-3.05 (m, 1H), 2.93 (ddt, J=14.0, 8.8, 5.7 Hz, 1H), 2.41 (s, 3H), 
2.22 (s, 3H).
 13
C NMR (176 MHz, dmso) δ 171.64, 170.54, 165.64, 162.97, 162.66, 160.36, 
157.40, 151.87, 148.81, 141.27, 139.26, 133.96, 132.88, 130.00, 129.49, 129.41, 128.64, 128.60, 
128.46, 128.16, 127.44, 127.24, 126.20, 125.64, 122.91, 121.86, 114.73, 108.53, 83.20, 55.28, 
44.49, 43.88, 43.63, 42.67, 41.33, 35.49, 34.64, 30.68, 28.22, 26.02, 25.97, 18.76. MS-ESI (m/z): 
[M + H]
+




Synthesis of 2.19: 2.18 (59.5 mg, 0.074 mmol) was stirred in DMF (0.30 mL). 2.2 was 
dissolved in DMF to make a 0.125 M solution. 2.2 in DMF (0.60 mL, 0.075 mmol) was added 
to 2.18 in DMF. The reaction mixture was stirred overnight. The crude reaction was purified by 
reverse-phase HPLC using a linear 20→80% acetonitrile + 0.1% TFA in water gradient. 
Lyophilization afforded 2.19 as a white solid (3.7 mg, 2.3% yield). Spectral data. MS-ESI 
(m/z): [M - H]
-





Synthesis of 2.5:  2.19 (3.7 mg, 0.0017 mmol) was added to an oven-dried flask. ACN (0.5 mL) 
was then added followed by TMS-Br (0.5 mL) and reaction mixture was stirred overnight. 
Water (0.5 mL) was then added and the reaction was again stirred for an hour. The solvent was 
then removed under reduced pressure. The reaction was purified by reverse-phase HPLC using a 
linear 20→80% acetonitrile + 0.1% TFA in water gradient. Lyophilization afforded 2.5 as a 
white powder (0.9 mg, 24% yield). Spectral data. HRMS-ESI (m/z): [M - H]
-
 calcd for 
C94H126ClN20O29PS, 2095.8007; found 2095.8074. 
 
 
Synthesis of 2.20: Compound 2.20 was synthesized on 0.2 mmol scale on Rink Amide AM 
resin (0.47 mmol/g) using standard Fmoc solid-phase peptide synthesis. Couplings were 
performed using DIEA and HBTU in NMP and were allowed to proceed for 30 minutes at room 
temperature. Fmoc deprotections were performed using piperidine in NMP and were allowed to 
proceed for 15 min at room temperature. The completeness of each coupling and deprotection 
was monitored by the Kaiser test. After deprotection of the final amino acid in the sequence, the 
peptide was capped by coupling on FITC (4 mg, 0.010 mmol) using DIEA in DMF (1 mL). 
Cleavage of the peptide from the resin with concomitant removal of all side chain-protecting 
33 
groups was accomplished with 6 mL of a 95% TFA, 2.5% H2O, and 2.5% TIPS solution for 45 
minutes twice. The TFA was mostly removed under reduced pressure. The product was 




Synthesis of 2.21:  2.20 was added to an oven-dried flask. ACN (0.5 mL) was then added 
followed by TMS-Br (0.5 mL) and reaction mixture was stirred overnight. Water (0.5 mL) was 
then added and the reaction was again stirred for an hour. The solvent was then removed under 
reduced pressure. The reaction was purified by reverse-phase HPLC using a linear 5→80% 
acetonitrile + 0.1% TFA in water gradient. Lyophilization afforded 2.21 as a white powder (2.2 
mg, 0.56% yield). Spectral data. HRMS-ESI (m/z): [M - H]
-
 calcd for C93H120N15O29PS 
1972.7762; found 1972.7802. 
 
Spectral Data for Compounds 




C NMR) for compounds are shown in Appendix A. 
 
General Biochemical Methods 
 Black, opaque-bottom 96 well plates were purchased from Nunc. All proteins were 
expressed in E.coli using previously published procedures.
28
 Data were obtained using Biotek 





Determination of Inhibitor IC50 Values against Src Family Kinases. 
 A continuous fluorescence assay was used to determine IC50.
27
 The reaction volume was 
100 μL consisting of 85 μL of enzyme in buffer, 2.5 μL of the appropriate inhibitor dilution 
(typically 10000, 3333.33, 1111.11, 370.37, 123.46, 41.15, 13.72, 4.57, 1.52, and 0 µM in 
DMSO), and 2.5 μL (1.8 mM in DMSO) of a substrate peptide (“compound 3” as described in 
Wang et al.)
27
. The reaction was initiated with 10 μL of ATP (1 mM in water), and reaction 
progress was immediately monitored at 405 nm (ex. 340 nm) for 10 minutes. Reactions had final 
concentrations of 30 nM enzyme, 45 μM peptide substrate, 100 μM ATP, 100 μM Na3VO4, 100 
mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-100 unless otherwise noted. The initial 
rate data collected was used for determination of IC50 values. For IC50 determination, the kinetic 
values were obtained directly from nonlinear regression of substrate-velocity curves in the 
presence of various concentrations of the inhibitor. The equation Y=Bottom + (Top-
Bottom)/(1+10^((LogEC50-X)*HillSlope)), X = log(concentration) and Y = binding; was used in 
the nonlinear regression unless otherwise noted. An IC50 value was determined for each inhibitor 
using at least three independent experiments. The individual IC50 values for the three runs were 
then averaged. A representative inhibition curve of a single run is shown in Appendix A. 
 
Determination of inhibitor IC50 Values Against c-Abl. 
 A continuous fluorescence assay was used to determine IC50.
27
 The reaction volume was 
100 μL consisting of 85 μL of enzyme in buffer, 2.5 μL of the appropriate inhibitor dilution 
(typically 10000, 3333.33, 1111.11, 370.37, 123.46, 41.15, 13.72, 4.57, 1.52, and 0 µM in 
DMSO), and 2.5 μL (2.4 mM in DMSO) of a substrate peptide.
31
 The reaction was initiated with 
10 μL of ATP (1 mM in water), and reaction progress was immediately monitored at 405 nm (ex. 
340 nm) for 10 minutes. Reactions had final concentrations of 30 nM enzyme, 60 μM peptide 
substrate, 100 μM ATP, 100 μM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% 
Triton X-100. The initial rate data collected was used for determination of IC50 values. For IC50 
determination, the kinetic values were obtained directly from nonlinear regression of substrate-
velocity curves in the presence of various concentrations of the inhibitor. The equation 
Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)), X = log(concentration) and Y = 
binding; was used in the nonlinear regression. An IC50 value was determined for each inhibitor 
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using at least three independent experiments. The individual IC50 values for the three runs were 
then averaged. A representative inhibition curve of a single run is shown in Appendix A. 
 
Determination of SH2 Peptide (2.21) Kd. 
 A fluorescence polarization assay was used to determine Kd of peptide 2.21. The reaction 
volume was 50 μL consisting of 49 μL of enzyme dilutions in buffer (50 mM Tris buffer (pH 8), 
10 mM NaCl, 5% Glycerol, 1 mM DTT) and 1.0 μL of 2.21 (10 mM in DMSO). The protein was 
plated to provide 2x dilutions. The peptide was then added and the plate was incubated on ice for 
1 hr. After 1 hr, fluorescence polarization was monitored at 528 nm (ex. 485 nm). Reactions had 
final concentrations of 200 nM 2.21. For Kd determination, the mPolarization values were plotted 
vs. varying protein concentrations. The equation Y=Bmax*X/(Kd + X), X = Protein 
concentration and Y = FP response; was used in the nonlinear regression. A single representative 
inhibition curve with error bars is shown in Appendix A. 
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An Allosteric Modulator of c-Src Tyrosine Kinase that Alters Global Conformation 
 
Abstract 
 We have identified a small molecule activator of the tyrosine kinase c-Src. It was 
identified via a screen of 1,000 Maybridge compounds. Importantly, this screen was carried out 
against three domain c-Src in order to identify compounds that could alter the global 
conformation of the kinase. After the initial screen, we used a protease accessibility assay to 
evaluate how the hits from the screen affected c-Src global conformation. Two of the hits were 
determined to cause an open conformation in c-Src. In turn, one of the inhibitors capable of 
opening c-Src also activated the enzyme. Furthermore, this activator was selective and improved 




 Kinases play a crucial regulatory role in a variety of cell processes. Dysregulation of 
these important enzymes can lead to a variety of disease states.
1,2
 ATP-competitive kinase 
inhibitors have been highly successful in treating a variety of cancers and a few other diseases.
3
 
One downfall of most kinase inhibitors, however, is that they almost all bind in the conserved 
ATP-binding pocket, and are, as a result, often promiscuous.
4,5
 In order to truly understand the 
role a kinase plays incellulo, it is important to have selective inhibitors. In Chapter II, we 
detailed the development of a selective bivalent inhibitor of the protein tyrosine kinase c-Src as 
an attempt to target other sites besides the ATP-binding pockets. Another method to study 
kinases outside the ATP-binding pocket is through the use of allosteric modulators. There are 
many allosteric kinase inhibitors; however, until very recently, c-Src did not have a known 
allosteric inhibitor.
6,7
 Furthermore, as we demonstrate in Chapter II, inhibitors can be used to 
explore the global conformation of kinases. 
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 c-Src is a cytosolic protein tyrosine kinase containing the catalytic kinase domain as well 
as two regulatory domains, SH2 and SH3.
8
 The conformation that these three domains adopt in 
relationship to each other can be referred to as the global conformation. As mentioned in 
Chapter II, c-Src can adopt two known global conformations, open and closed (Figure 1.1).
9,10
 
The phosphorylation state of c-Src is highly connected to global conformation. The 
autophosphorylation site Tyr416 is important for full activity of c-Src,
11
 and the phosphorylation 
site Tyr527 is responsible for binding the SH2, which closes the kinase.
9
 It has been shown that 
ATP-competitive inhibitors have the ability to modulate the global conformation of protein 
tyrosine kinases, despite the fact that they bind in the kinase domain.
12
 We wanted to identify an 
inhibitor capable of modulating the global conformation of c-Src via binding in an allosteric 
pocket. 
 
Hit Identification and Assessment of Global Conformation 
 We tested a library of 1,000 compounds from Maybridge for compounds that would bind 
three domain c-Src.
a
 Using three domain c-Src was crucial as opposed to screens that use only 
the kinase domain,
5,13
 since we desired a compound that would affect global conformation. We 
used a thermal shift assay to determine compound binding to c-Src. The library consisted of 13 
plates, each of which was analyzed separately, with its own set of controls. The positive control 
was dasatinib and the negative control was 1% DMSO vehicle. A hit was defined as a compound 
with a Tm that was greater than 3 standard deviations from the negative control. An example of 
the hits from one plate is shown in Figure 3.1. All of the other plates were plotted and analyzed 
in the same fashion (Appendix B). Using our 3 standard deviation cutoff, the screen yielded 37 
hits. Structures for the 37 hits are shown in Table B1. 
                                                          
a
 Michael P. Agius made several direct contributions to the work in this chapter including: helping to run the screen, 
establishing the protease accessibility assay, and determining the half-lives of 3 hits using 5 time-point curves. 
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Figure 3.1. Tm for Plate 1 Compounds. Every compound is shown in blue with hits highlighted in yellow. The Tm 
for the negative control is shown in red, the Tm for the positive control is shown in green, and the 3 standard 
deviation cutoff for hits is shown in black.  
 
 After identification of 37 hits that bound c-Src, we assessed the effect that the hits had on 
the global conformation of c-Src. We used a protease accessibility assay developed in our lab. It 
is simple, low cost, and medium throughput. It is based on the accessibility of the linker between 
the kinase and SH2 domains. The protease thermolysin is known to cleave c-Src at a site on the 
linker.
14
 Cleavage of the kinase over time by thermolysin can be evaluated by measuring the 
intensity of the full-length protein via SDS. The band intensity can then be plotted vs. time to 
obtain a half-life curve. A construct that is more open will have a more exposed linker, be 
proteolyzed more quickly by thermolysin, and thus have a shorter half-life (Figure 3.2). We used 
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Figure 3.2. Controls for thermolysin proteolysis accessibility assay. a)The gel showing the disappearance of the protein 
band for the open, WT, and closed controls for c-Src along with  (b) the corresponding half live curves and illustrations 
of the constructs. 
 
 For the controls in Figure 3.2, we assessed the presence of protein at 10 different time 
points. In order to evaluate our 37 hits more quickly, we assessed the hits using 5 time points. Of 
the 37 initial hits, 9 compounds were different from apo Src by a standard deviation. These were 
re-evaluated using the full 10 time point curves previously established. The half-life curves are 
shown in Appendix B. When re-evaluated, we decided to only pursue the two most open hits. 












Figure 3.3. Hits capable of altering the global conformation of three domain c-Src. Compounds 1-E8 and 4-A11 
that both adopt an open conformation compared to apo c-Src are shown with their half-life curves. 
 
Activity of 1-E8 in 3D Src 
 Once we had established 1-E8 and 4-A11 as hits capable of stabilizing an open 
conformation in c-Src, we tested them against three domain c-Src using a continuous activity 
assay.
15
 We did not observe any effect for 4-A11; however, gratifyingly, 1-E8 activated c-Src 
with EC50 = 90 μM. These data confirmed our hypothesis that a compound capable of stabilizing 
an open conformation in c-Src would activate the kinase. Furthermore, 1-E8 did not seem to be 
ATP-competitive as a change in the concentration of ATP had no effect upon the EC50 
(Appendix B). 
 We also looked at the effect of different phosphorylation-states of c-Src. As mentioned 
earlier, the autoregulation of c-Src is known to be controlled by the phosphorylation-states of c-
Src. c-Src is down regulated when Tyr527 is phosphorylated and up-regulated when Tyr416 is 
phosphorylated.
9,10
 We saw that 1-E8 had no effect upon pY527 and it had a very small 
inhibitory effect upon pY416 (IC50 = 930 μM). These data suggest several things about activator 
1-E8. First, knowing that pY419 is open and active, it is reasonable to expect that 1-E8 would 
not be able to activate the kinase further, exhibiting very little effect. Furthermore, its inability to 
activate pY527 suggests that 1-E8 may bind somewhere at the interface between the kinase 
domain and SH2/SH3 domains. The fact that 1-E8 cannot bind the closed conformation of c-Src 
indicates a binding site inaccessible when the kinase is closed but accessible in the apo kinase. 
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Identification of Possible Binding Site 
 Focal adhesion kinase (FAK) is known to be a substrate of c-Src, and is known to 
activate c-Src.
16
 The linker between the FERM domain and kinase domain of FAK contains a 
binding site for the SH3 domain of c-Src as well as a phosphotyrosine binding site for the SH2 
domain of c-Src (Tyr397).
7,17
 Once we knew that that 1-E8 cannot bind when c-Src adopts a 
closed conformation, we hypothesized that it would bind in the same location on c-Src as a 
pFAK peptide.
7
 We again determined the EC50 of 1-E8 with a competitive, constant 
concentration of the pFAK peptide. As shown in Figure 3.4b, the addition of pFAK peptide 
eliminates the activator activity of 1-E8. This suggested to us the possibility that 1-E8 does in 
fact bind somewhere at the interface between the kinase domain and SH2/SH3 domains. To 
further establish the binding site of 1-E8, we determined the EC50 of c-Src SH2 peptide 2.21, 
with and without a constant concentration of 1-E8. Without 1-E8, we determined the EC50 of 
2.21 to be 100 nM, while it was 1000 nM in the presence of 100 μM 1-E8 (Appendix B). This 
suggests that 1-E8 binds within the SH2 domain, which is consistent with the observation that it 








Figure 3.4. FAK and 1-E8 Competition. a) Structure of FAK with pFAK Src binding peptide highlighted (b) EC50 
curves for 1-E8 with and without competing pFAK peptide 
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Selectivity and In cellulo Effect 
 We used two homologous kinases, c-Abl and Hck, to evaluate the selectivity of 1-E8. As 
mentioned earlier, selectivity is an important feature for using kinase inhibitors in a cellular 
environment. As stated in Chapter II, both c-Abl and Hck contain SH2 domains that bind 
phosphotyrosine. Given its small size and the fact that it competes with 2.21, we hypothesized 
that 1-E8 would bind in the phosphotyrosine-binding pocket within the SH2 domain of c-Src, 
and similarly, c-Abl and Hck. We found, however, that 1-E8 had no effect upon c-Abl 
(Appendix B) and a very minimal inhibitory effect upon Hck (IC50 = 550 ± 100 μM). This 
suggests that 1-E8 competes with 2.21 binding to the SH2 domain of c-Src through some 
mechanism other than the phosphotyrosine-binding pocket. Additionally, it further elaborates 
upon the findings in Chapter II that c-Src and Hck have differences in their global 
conformations. Upon finding that 1-E8 is selective for c-Src over homologous kinases, we 
wanted to test it in a c-Src dependent cell line. 
 In HT-29 cells (a c-Src dependent colon cancer cell line)
18
, 1-E8 has no observable effect 
(GI50 > 10 μM, Appendix B). We proposed, however, they 1-E8 might be able to act 
cooperatively in cells with other inhibitors. We have shown that Das-DFGO-II
19
 developed by 
our lab as part of a matched inhibitor set causes an open conformation in kinases (Chapter V). 
We determined the GI50 of Das-DFGO-II in HT-29 cells and also determined its GI50 with the 
addition of 10 μM 1-E8. We observed a decrease in the GI50 of Das-DFGO-II by three fold from 
157 nM to 52 nM with the addition of 1-E8. What is striking about these data is the fact that at 
10 μM 1-E8 has no effect on HT-29 cells. This lends further credence to the ability of 1-E8 to 
affect the global conformation of c-Src. It seems likely that 1-E8 was able to open and activate c-
Src in a way that allowed an inhibitor also known to bind to an open conformation (Das-DGFO-
II) to bind better and inhibit the growth of c-Src dependent cells better. 
 
Conclusions 
 Using a medium throughput screen, we identified a small molecule allosteric activator or 
the tyrosine kinase c-Src. We screened a 1,000 compound Maybridge against full-length c-Src 
using Thermofluor. We identified 37 hits that changed the Tm by greater than 3 standard 
deviations from the negative control. These hits were then analyzed using a protease accessibility 
assay to determine their effect on the global conformation of full-length c-Src. From the 37 hits, 
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two were seen to cause an open conformation in c-Src. Only one of them had an effect upon the 
activity of c-Src. This hit (1-E8) activated c-Src with a double-digit micromolar EC50. This was 
an excellent conformation of results from the protease assay. One would predict that a small 
molecule that caused the kinase to adopt an open conformation would also activate the kinase. 
Furthermore, 1-E8 was specific to c-Src, against homologous kinases, in its ability to activate the 
enzyme. Additionally, it interferes with binding both of a pFAK peptide and a SH2 binding 
peptide (2.21) suggesting a possible binding site. Most exciting was the ability to correlate the 
global conformation that a small molecule could induce in a kinase with its effect upon kinase 
activity. 
  
Materials and Methods 
 
General Biochemical Methods 
 Black, opaque-bottom 96 well plates were purchased from Nunc. Black, 384 well plates 
for Thermofluor were purchased from Thermoscientific. All proteins were expressed in E.coli 
using previously published procedures.
20
 Data were obtained using Biotek Synergy Mx and 
Biotek Synergy 4 plate readers. Curve fitting was done using Graphpad Prism 6 software. 
 
Determination of Tm for Maybridge Library Against Full-Length c-Src. 
 A thermal shift assay was used to determine compound Tm. The reaction volume was 5 
μL consisting of 4 μL of enzyme/1-anilino-8-naphthalenesulfonate (ANS) mix in buffer plus 1 
μL of inhibitor dilution. Stock compound plates of 10 mM compound in 100% DMSO were 
diluted 1:20 in buffer before being added to the reaction mix. 1.5 μL of silicon oil was added to 
the top of every well to prevent evaporation and the plate was centrifuged at 1000xg for 1 min. 
All compounds were tested in quadruplicate in a 384 well plate. Reactions had final 
concentrations of 0.2 mg/mL enzyme, 0.2 mM ANS, 50 mM Tris buffer (pH 8), 100 mM NaCl, 
5% glycerol, and 1 mM DTT unless otherwise noted. Using a Thermofluor instrument (Johnson 
& Johnson Pharmaceutical Research and Development, L.L.C), plates were heated from 25-80°C 
with 1 min at each degree with a shutter closed image taken every degree. Tm values were 
determined using Thermofluor++ ver 1.3.7 software, which plotted fluorescence intensity vs. °C. 
Hits were defined as compounds that had a Tm that was greater than 3 standard deviations from 
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the DMSO negative control. Tm values for every plate along with negative and positive controls 
are shown in Appendix B. 
 
Determination of Inhibitor IC50 Values against Src Family Kinases. 
 A continuous fluorescence assay was used to determine IC50.
15
 The reaction volume was 
100 μL consisting of 85 μL of enzyme in buffer, 2.5 μL of the appropriate inhibitor dilution 
(typically 10000, 3333.33, 1111.11, 370.37, 123.46, 41.15, 13.72, 4.57, 1.52, and 0 µM in 
DMSO), and 2.5 μL (1.8 mM in DMSO) of a substrate peptide (“compound 3” as described in 
Wang et al.).
15
 The reaction was initiated with 10 μL of ATP (1 mM in water), and reaction 
progress was immediately monitored at 405 nm (ex. 340 nm) for 10 minutes. Reactions had final 
concentrations of 30 nM enzyme, 45 μM peptide substrate, 100 μM ATP, 100 μM Na3VO4, 100 
mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-100 unless otherwise noted. The initial 
rate data collected was used for determination of IC50 values. For IC50 determination, the kinetic 
values were obtained directly from nonlinear regression of substrate-velocity curves in the 
presence of various concentrations of the inhibitor. The equation Y = Bottom + (Top - 
Bottom)/(1 + 10
(X-LogIC50)
), X = log(concentration) and Y = binding; was used in the nonlinear 
regression unless otherwise noted. An IC50 value was determined for each inhibitor using at least 
three independent experiments. The individual IC50 values for the three runs were then averaged. 
A representative inhibition curve of a single run is shown in Appendix B. 
 
Determination of Inhibitor IC50 Values against 3D Abl. 
 A continuous fluorescence assay was used to determine IC50.
15
 The reaction volume was 
100 μL consisting of 85 μL of enzyme in buffer, 2.5 μL of the appropriate inhibitor dilution 
(typically 10000, 3333.33, 1111.11, 370.37, 123.46, 41.15, 13.72, 4.57, 1.52, and 0 µM in 
DMSO), and 2.5 μL (2.4 mM in DMSO) of a substrate peptide.
21
 The reaction was initiated with 
10 μL of ATP (1 mM in water), and reaction progress was immediately monitored at 405 nm (ex. 
340 nm) for 10 minutes. Reactions had final concentrations of 60 nM enzyme, 60 μM peptide 
substrate, 100 μM ATP, 100 μM Na3VO4, 100 mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% 
Triton X-100. The initial rate data collected was used for determination of IC50 values. For IC50 
determination, the kinetic values were obtained directly from nonlinear regression of substrate-
velocity curves in the presence of various concentrations of the inhibitor. The equation Y = 
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Bottom + (Top - Bottom)/(1 + 10
(X-LogIC50)
), X = log(concentration) and Y = binding; was used in 
the nonlinear regression. An IC50 value was determined for each inhibitor using at least three 
independent experiments. The individual IC50 values for the three runs were then averaged. A 
representative inhibition curve of a single run is shown in Appendix B.  
 
General procedure for BODIPY probe EC50 determination. 
 A fluorescence polarization was used to determine EC50 values. Reaction volumes of 50 
μL were used in 96-well plates. 34 μL of buffer (50 mM Tris buffer (pH 8), 10 mM NaCl, 5% 
Glycerol, 1 mM DTT) was added to a single row, followed by 15 μL of enzyme (3.3X 
concentration) in buffer with 2-fold dilutions (typically 150, 75, 37.5, 18.75, 9.375, 4.69, 2.34, 
1.17, 0.586, 0.293, and 0 nM final well concentration). Then, 1 μL of a 500 nM stock of the 
appropriate dasatinib analog BODIPY probe in DMSO was added (2% DMSO final). Wells were 
incubated on ice for 30 minutes prior to fluorescence polarization read (ex/em 485/535 nm). 
After the initial read, 1 μL of 51 μM GNF-2 was added to each well for a final concentration of 1 
μM GNF-2. Following another 30 minute incubation on ice, the wells were read again. Reactions 
had final concentrations of 10 nM BODIPY-probe, 50 mM Tris buffer (pH 8), 10 mM NaCl, 5% 
Glycerol, 1 mM DTT. For Kd determination, the mPolarization values (normalized to the 0 nM 
protein control) were plotted vs. varying protein concentrations. The equation Y = (Bmax * 
X)/(EC50 + X), X = Protein concentration and Y = FP response; was used in the nonlinear 
regression. In two separate runs, the EC50 value was determined using at least four independent 
experiments. The EC50 value determined from the two separate runs was averaged. A single 
representative inhibition curve with error bars is shown in Appendix B. 
 
General Procedure for Proteolysis Half-Life Determination 
 c-Src was diluted in proteolysis buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.5 mM 
CaCl2) to yield a final protein concentration of 2 µM (for 5 point curves this solutions was split 
in half). This was followed by the addition 1 μL of a 10 mM stock of each compound being 
tested to give a final concentration of 57 μM compound (113 μM for 5 point curves). 15 µL of 
the protein/compound solution was added to 5 µL of 50 mM EDTA as the 0 min time point. The 
proteolysis reaction was initiated by adding Thermolysin (purchased from Promega, catalog 
number: V4001) from a 3.8 μM stock solution to a final concentration of 50 nM. At various time 
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points (2, 5, 10, 30, 60, 90, 120, 180, and 240 mins for full curves and 5, 30, 60, 90 mins for 5 
point curves), 15 µL of the proteolysis reaction was added to 5 µL of 50 mM EDTA to quench 
proteolysis. The quenched samples were analyzed by SDS-PAGE (12 % Bis-Tris gel in MES 
running buffer, staining with coomassie blue). Band intensities were analyzed by ImageJ 
imaging software. Percent protein remaining was plotted against time and fit to an exponential 
decay equation using GraphPad Prism software to obtain half-lives of each protein. Each half-life 
was determined using a single experiment. The half-life curves are shown along with the gel for 
each apo protein (Appendix B).  
 
General procedure for cellular characterization. 
1. Cell culture and seeding: HT-29 cells were cultured in McCoy's 5A media with 10% FBS. 
Media was aspirated and cells were washed with 12.5 mL of DPBS, which was then aspirated. 2 
mL of 0.05% trypsin-EDTA was added to the cells and incubated at 37°C and 5% CO2 until cells 
detached. 5 mL of prepared media was added to the cells in trypsin-EDTA and an aliquot of the 
cells was mixed with Trypan Blue solution and the cell number was quantified using a 
hemocytometer. The cells were plated 100 μL in each well at 30,000 cells/mL so that each well 
contained 3,000 cells. The cells were plated into sterile, clear bottom 96 well plates and 
incubated overnight at 37°C and 5% CO2 overnight for cells to re-adhere. Additionally, 3 wells 
were created containing 100 μL of media with no cells. 
2. Dosing: The compounds were made in 100% DMSO at 1,000X the final concentrations that 
were desired for the assay generally covering a concentration range of 6 log units. These DMSO 
stocks were diluted 10X in McCoy's 5A media. 1 μL of the compound diluted in media was 
added to each well for a final concentration of 0.1% DMSO. The wells containing only media 
were not dosed. In general, each compound concentration was dosed in triplicate wells. The 
plates were returned to normal culture conditions (per ATCC) for 72 hours. 
3. Assay: After 72 hours, the plates were removed from the incubator, and 10 μL of WST-1 
reagent was added to each well. The plates were returned to the incubator and the color change 
was visually monitored for 0.5 – 2 hours. When sufficient color change had occurred, the plates 
were shaken on a plate shaker for 30 seconds, and absorbance at 450 and 630 nm was read in a 
Biotek Synergy 4 plate reader. The absorbance at 630 nm was subtracted from the absorbance at 
450 nm. 
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4. Data Analyses: The average absorbance value from wells containing media without cells was 
subtracted from the absorbance value for all the wells containing cells. The absorbance values 
were then taken as a percentage of the absorbance for the vehicle wells (0.1% DMSO - no 
compound). The percent compared to vehicle was then plotted vs. log[Concentration (M)]. Data 
analyses and curve fitting were performed using Graphpad Prism 6. In two separate runs, the 
GI50 value was determined using at least three independent experiments. The GI50 value 
determined from the two separate runs was averaged. A single representative inhibition curve 
with error bars is shown in Appendix B. 
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 We developed a bivalent inhibitor for the protein tyrosine kinase c-Abl that interacts with 
the myristate and ATP binding pockets. Our approach transformed a dual c-Src/c-Abl ATP-
competitive inhibitor into a bivalent inhibitor that was 100X more potent for c-Abl than c-Src. 
Furthermore, the bivalent inhibitor was 25X more potent for c-Abl than the initial ATP-
competitive inhibitor. Finally, and most important for its use as a tool to study c-Abl in cells, this 
bivalent inhibitor is cell permeable with a cellular therapeutic index of 14. 
 
Introduction 
 Protein kinases play important roles in both healthy and diseased cell signaling. There is, 
however, a lack of selective kinase inhibitors, which makes it difficult to pharmacologically 
study kinase signaling.
1–3
 Almost all reported kinase inhibitors bind to the conserved ATP-
binding site,
4
 which results in most ATP-competitive kinase inhibitors being promiscuous and 
binding undesired off-targets.
4–6
 Interacting with elements outside the conserved ATP pocket has 
been recognized as an excellent strategy to improve the selectivity of kinase inhibitors.
7–9
 
 The nonreceptor tyrosine kinase c-Abl plays an important role in many crucial cell 
processes, and fusion protein BCR-Abl is the causative factor in Chronic Myelogenous 
Leukemia (CML). ATP-competitive inhibitors imatinib, nilotinib, and dasatinib have been highly 
successful for the treatment of CML. Conversely, knowing the advantages of binding outside the 
conserved ATP-pocket, Gray and coworkers identified an allosteric inhibitor, GNF-2, that binds 
in the myristate pocket of c-Abl.
10–12
 The myristate pocket is located within the kinase domain of 
c-Abl and serves as a means of autoregulation via the myristoylated N-terminal tail (a means of 
autoregulation unique to c-Abl). Crystallographic data have shown that GNF-2 causes a kinking 




In the native system, this action causes the engagement of the SH2 and SH3 domains with the I-
helix and inhibition of the kinase domain.
13
 These data suggests that GNF-2-bound Abl kinase 






Figure 4.1. Structural effect of GNF-2 binding to c-Abl. Crystal structures showing the kinase domain of c-Abl with 
ATP-competitive inhibitors (blue) bound demonstrating a) an extended I-helix (cyan) when GNF-2 is not bound 
(PDB: 2F4J) compared to b) a kinked I-helix (cyan) when GNF-2 (magenta) is bound (PDB: 3K5V)  
 
 Bivalent inhibitors that interact with elements outside the ATP-pocket have proven 
excellent tools to study kinases.
14–17
 There are reported examples of bivalent inhibitors of c-Abl; 
however these inhibitors have large protein-based linkers,
15,18
 and we wanted to create a small-
molecule bivalent inhibitor of c-Abl. Our strategy involved a dual c-Src/c-Abl ATP-competitive 
inhibitor linked to GNF-2. We reasoned that due to the unique selectivity of GNF-2, we could 
transform a potent yet promiscuous ATP-competitive inhibitor into a highly potent and selective 
inhibitor of c-Abl. We further hoped to use this inhibitor to inhibit c-Abl in cells. 
 
Bivalent Inhibitor Design 
 In Chapter 2, we designed a bivalent inhibitor of the kinase c-Src that utilized a dasatinib 
analog with a pendant cyclooctyne (2.18).
17
 Given that dasatinib is a dual c-Src/c-Abl inhibitor, 
we decided to use this analog to create a bivalent inhibitor of c-Abl, further demonstrating the 
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modularity of our previous approach. Additionally, by conjugating 2.18 to GNF-2, we could 
hopefully impart a great deal of selectivity for c-Abl over c-Src. To enable conjugation to GNF-
2, we synthesized 4.1, a GNF-2 analog with a PEG linker containing a terminal azide (Scheme 
4.1). Strain-mediated click chemistry made possible by the pendant cyclooctyne of 2.18 was then 
used to construct bivalent inhibitor 4.2. We had some concerns that the cyclooctyne functionality 
of 2.18 might render it too reactive to use in biochemical or cellular assays. To combat this 
problem, we synthesized analog 4.3 (Figure 4.2) where benzyl azide is conjugated to the 
cyclooctyne creating a benzyl triazole. 
  
Scheme 4.1. Strain-promoted click cycloaddition of ATP-competitive cyclooctyne 2.18 and azido-GNF-2 4.1 afford 
triazole-linked bivalent inhibitor 4.2. 
 
 
Figure 4.2. Structure of 4.3, benzyl triazole protected version of cyclooctyne dasatinib analog 2.18 
 
Biochemical Characterization of Bivalent Inhibitor 
 GNF-2 only has an inhibitory effect with full-length c-Abl; however, it can bind to the 
kinase domain construct of c-Abl without inhibiting the activity of the enzyme.
19
 Thus, we 
hypothesized that bivalent inhibitor 4.2 would show an improvement in binding compared to 






inhibitors 4.1-4.3 against both constructs. Using a continuous activity assay,
20
 we observe that 
bivalent inhibitor 4.2 is approximately 10X more potent than 4.1 and 4.3 in both constructs 
(Table 4.1). Furthermore, we determined the IC50 for 4.2 against just the kinase domain of c-Abl 
but with 8 μM competing GNF-2. As expected (Table 4.1), the IC50 of 4.2 increased drastically 
when forced to compete with GNF-2 indicating that the GNF-2 piece is binding in the kinase 
domain. Additionally, it is known that c-Src is myristoylated similarly to c-Abl, and has a 
binding pocket for myristate.
21
 It is known that GNF-2 cannot inhibit c-Src presumably due to 
the different mechanisms of autoregulation in c-Src and c-Abl.
13,22
 We hypothesized, however, 
that GNF-2 could possibly bind c-Src without inhibiting activity. Bivalent inhibitor 4.2 gave us 
the opportunity to test this hypothesis. Given our hypothesis, bivalent inhibitor 4.2 should be at 
least, if not more, potent than the ATP-competitive inhibitor 4.3 for the kinase domain of c-Src. 
We did not observe this; 4.2 showed poor inhibition for c-Src (Table 4.1). To further illustrate 
the point that the GNF-2 portion could not bind c-Src, 4.2 did not get any worse when forced to 
compete with 8 μM free GNF-2. 
Table 4.1. IC50 values for inhibitors 4.1-4.3 against kinase domain (KD) and three domain c-Abl. They are shown with 
and without competing GNF-2 as well as kinase domain c-Src. DNI = Did not inhibit. 










KD + 8 μM 
GNF-2 
4.1 DNI 320     
4.2 26 <30 1,100  1,200 1,700 
4.3 150 420   360  
 
 
 In order to further verify that both portions of the bivalent inhibitor were binding as 
expected, we performed additional experiments with various mutants of c-Abl in the myrsitate 
pocket that are known to block GNF-2 binding.
10,12
 In full-length mutant c-Abl, we show that 
when GNF-2 cannot bind, the IC50 of 4.2 gets worse and corresponds relatively well to the IC50 
of 4.3 (Table 4.2). In kinase domain c-Abl, the IC50 for 4.2 gets markedly worse even compared 
to 4.3. This is a little unexpected given that the ATP-competitive portion of 4.2 should still bind; 
however, the same trend was seen when 4.2 was tested against the kinase domain of c-Abl with 
competing GNF-2 (Table 4.1). A possible explanation could be that when the GNF-2 portion of 
4.2 is not able to bind, there is a lot of extra chemical matter present that interferes with the 
binding of the ATP-competitive portion. This is probably not as significant when using the larger 
full-length construct of c-Abl. 
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Table 4.2. IC50 values for inhibitors 4.1-4.3 against c-Abl mutants. These mutants are known to abrogate GNF-2 
binding. 
 Abl IC50 (nM) 
 Kinase Domain  Three Domain 
 4.3 4.1 4.2  4.3 4.1 4.2 
WT 150 DNI 26  230 320 <30 
A337N 270 DNI 1,700  290 240,000 550 
P465S 190 700,000 900  220 110,000 830 
E505K 230 440,000 700  170 120,000 160 
 
 
 Due to the limits of our activity assay based on protein concentration, we were unable to 
observe the full effects of our bivalent inhibitor against full-length c-Abl (Table 4.1). To resolve 
this issue, we utilized a commercial binding assay performed in reticulocyte lysate with ~ 5 mM 
ATP (Luceome Biotechnologies, Tucson, AZ)
23,24
 to measure the affinity of bivalent inhibitor 
4.2. In our activity assay, we could only determine the IC50 against full-length c-Abl to be less 
than 30 nM, which was very similar to kinase domain. We hypothesized that 4.2 should be more 
potent against full-length c-Abl than kinase domain since GNF-2 cannot inhibit kinase domain c-
Abl. These data from Luceome Biotechnologies confirm our hypothesis (Table 4.3). The IC50 for 
4.2 in kinase domain was similar to what we had determined using our activity assay, but without 
the limits of our assay, the IC50 for 4.2 against full length c-Abl was 1.2 nM, a 10X 
improvement. Furthermore, with full length c-Abl, bivalent inhibitor 4.2 is again almost 10X 
more potent than dasatinib, illustrating the importance of both binding pieces. Additionally, in 
full length c-Abl, bivalent inhibitor 4.2 is 25X more potent than dasatinib analog 2.18. To further 
show the binding importance of the GNF-2 piece of 4.2, with 20 μM competing GNF-2, the IC50 
of dasatinib remains relatively the same while the IC50 of 4.2 gets 25X worse (Table 4.3).  
Table 4.3. IC50 values for dasatinib and inhibitors 4.2 and 2.18 as determined using Luceome Biotechnologies 










dasatinib 2.7 9.1 5.0  18 
4.2 11.8 1.2 31.1  112 
2.18  32    
 
 
Selectivity of Bivalent Inhibitor 4.2 
 We also used the data that we obtained from Luceome to assess the selectivity of 4.2. 
dasatinib is known to be a dual c-Src/c-Abl inhibitor. For this reason, we decided to evaluate the 
selectivity of bivalent inhibitor 4.2 for c-Abl over c-Src. As shown in Table 4.3, dasatinib is 
equipotent for full-length c-Abl and c-Src. Impressively, bivalent inhibitor 4.2 is 100X more 
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potent for full-length c-Abl than c-Src. By adding the GNF-2 portion, which is highly selective 
for c-Abl, we were able to make a previously dual c-Src/c-Abl inhibitor much more potent for c-
Abl than c-Src. 
  
Cellular Characterization of Bivalent Inhibitor 4.2 
 Given their large size and often peptidic nature, very few bivalent inhibitors are cell 
permeable.
16,17
 With both binding pieces of bivalent inhibitor 4.2 being small molecules, we 
believed there was the potential for it to be cell permeable. To test the cell permeability of 4.2, 
we utilized a commercial cellular target engagement assay that is performed in HEK 293 cells 
containing ABL1 (DiscoverX Corporation, San Francisco, CA). We observed an impressive IC50 
of 15 nM, demonstrating that 4.2 is in fact a cell permeable and effective c-Abl inhibitor. We 
also tested 4.2 in BCR-Abl Ba/F3 cells, a common cell line to test c-Abl inhibitor. We observed 
that 4.2 inhibits BCR-Abl Ba/F3 cell growth with a modest GI50 value of 700 nM. Additionally, 
in parental Ba/F3 cells, 4.2 has a GI50 > 10 μM. This gives it a respectable therapeutic index of 
>14. We were excited that 4.2 was cell permeable and will continue to explore its cellular effect. 
 
Conclusions 
 We have developed a bivalent inhibitor of c-Abl that interacts with both the ATP-pocket 
and the regulatory, myristate pocket. The ATP pocket is conserved across the kinome;
4
 however, 
the autoregulation of c-Abl via its myristate pocket is unique. As such, by linking a dual c-Src/c-
Abl ATP-competitive inhibitor to GNF-2 we were able to gain a high degree of selectivity for c-
Abl. This bivalent inhibitor also showed significant improvement in potency over either binding 
piece alone. Furthermore, through multiple methods (competition with GNF-2 and site-directed 
mutagenesis) we validated that both binding pieces were important for the improvement in 
potency. Additionally, unlike most bivalent inhibitors, our created bivalent inhibitor is cell 
permeable. It has a modest GI50 in BCR/Abl Ba/F3 cells and is entirely ineffective in non-






Materials and Methods 
 
General Synthetic Methods 
 Unless otherwise noted, all reagents were obtained via commercial sources and used 
without further purification. All 
1
H NMR spectra were measured with a Varian MR400 or Inova 
500 spectrometer. Mass Spectrometry (HRMS) was carried out by the University of Michigan 






Scheme 4.2. Synthetic Scheme for Compound 4.1 
 




Synthesis of 4.5: DMF (9.0 mL) was added to a round-bottom flask containing 4.4 (400 mg, 
1.07 mmol), 1-boc-ethylenediamine (0.14 mL, 0.89 mmol), and PyBOP (562.4 mg, 1.07 mmol). 
DIEA (0.31 mL, 1.78 mmol) was then added and the reaction was stirred overnight. The reaction 
mixure was brought up in 50 mL of ethyl acetate and washed with 10% citrate, sat. bicarb, and 
brine. After drying over Na2SO4, the product was purified by silica gel chromatography using a 
Biotage Isolera One (linear gradient 30 → 80% ethyl acetate in hexanes). The pure fractions 
were combined and the solvent was removed under reduced pressure to yield 4.5 as a white solid 
(190 mg, 41% yield). Spectral data. 
1
H NMR (500 MHz, DMSO-d6) δ 9.95 (s, 1H), 8.77 (s, 
4.1 
4.4 4.5 4.6 
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1H), 8.65 (t, J = 5.6 Hz, 1H), 8.51 (s, 1H), 8.18 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 
7.86 (dd, J = 9.5, 2.9 Hz, 2H), 7.63 (t, J = 7.8 Hz, 1H), 7.43 – 7.29 (m, 3H), 6.94 (t, J = 5.9 Hz, 
1H), 3.31 (s, 2H), 3.13 (q, J = 6.3 Hz, 2H), 1.37 (s, 9H). MS-ESI (m/z): [M + H]
+
 calcd for 
C25H26F3N5O4 518.2010; found 518.2009.  
 
Synthesis of 4.6: 4.5 (77.6 mg, 0.15 mmol) was added to an oven-dried flask. DCM (1.0 mL) 
and TFA (1.0 mL) were added followed by TIPS (20 μL, 0.008 mmol). The resulting solution 
was stirred for 1 hour. The solvent was then removed under reduced pressure. The resulting 
residue was carried forward crude without purification assuming theoretical yield. 
 
Synthesis of 4.1: DMF (1.8 mL) was added to a round-bottom flask containing N3-PEG7-CO2H 
(103.4 mg, 0.18 mmol), 4.6 (62.7 mg, 0.15 mmol), and PyBOP (95.1 mg, 0.18 mmol). DIEA 
(0.26 mL, 1.5 mmol) was then added and the reaction was stirred overnight. The reaction 
mixture was purified by reverse-phase HPLC using a linear 20→80% acetonitrile in water 
gradient. Lyophilization of pure fractions afforded 4.1 as an off-white solid (81.5 mg, 57% 
yield).  Spectral Data. 
1
H NMR (500 MHz, DMSO-d6) δ 9.94 (s, 1H), 8.83 – 8.74 (m, 2H), 8.52 
(t, J = 1.8 Hz, 1H), 8.26 (t, J = 5.7 Hz, 1H), 8.19 (dt, J = 7.9, 1.4 Hz, 1H), 8.07 (t, J = 5.9 Hz, 
1H), 7.98 (dt, J = 7.9, 1.4 Hz, 1H), 7.89 – 7.82 (m, 2H), 7.64 (t, J = 7.7 Hz, 1H), 7.40 – 7.30 (m, 
3H), 3.95 (d, J = 4.2 Hz, 4H), 3.58 (dd, J = 5.6, 4.3 Hz, 2H), 3.56 – 3.45 (m, 28H), 3.45 – 3.35 
(m, 5H), 3.26 (q, J = 6.0 Hz, 2H). MS-ESI (m/z): [M + H]
+
 calcd for C42H58F3N9O13 954.4179; 
found 954.4176.  
 
 
Synthesis of 4.2: 4.1 (1.3 mg, 0.001 mmol) was added to a stirred solution of 2.18 (1.0 mg, 
0.001 mmol) in MeOH (0.1 mL). The resulting reaction mixture was stirred overnight. The 
solvent was then removed under reduced pressure and the resulting residue was brought up in 
DMSO and purified by reverse-phase HPLC using a linear 30→90% acetonitrile in water 
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gradient. Lyophilization of pure fractions afforded 4.2 as a white solid (0.63 mg, 36% yield).  
Spectral Data. MS-ESI (m/z): [M + H]
+
 calcd for C84H98ClF3N18O17S 1755.6791; found 
1755.6751.  
 
Synthesis of 4.3: Benzyl azide (0.03 mL, 0.24 mmol) was added to a stirred solution of 2.18 
(21.1 mg, 0.03 mmol) in MeOH (0.2 mL). The resulting reaction mixture was heated to 70°C 
overnight. The solvent was then removed under reduced pressure and the resulting residue was 
brought up in DMSO and purified by C18 silica gel chromatography using a Biotage Isolera One 
(linear gradient 30 → 90% acetonitrile in water). Lyophilization of the fractions comprising the 
lone peak were further purified by reverse-phase HPLC using a linear 30→90% acetonitrile + 
0.1% TFA in water gradient. Lyophilization of pure fractions afforded 4.3 as a white solid (5.2 
mg, 19% yield).  Spectral Data. 
1
H NMR (500 MHz, dmso) δ 11.56 (s, 1H), 9.90 (s, 1H), 8.23 
(s, 1H), 7.59 (ddt, J = 42.5, 21.8, 6.5, 6.5 Hz, 5H), 7.40 (j, J = 7.7 Hz, 1H), 7.28 (tt, J = 14.3, 
14.3, 4.2, 4.2, 7H), 6.95 (d, J = 7.3 Hz, 2H), 6.08 (s, 1H), 5.79 (dd, J = 20.3, 16.5 Hz, 2H), 5.66 
(d, J = 16.0 Hz, 1H), 4.40 (d, J = 16.8Hz, 1H), 3.54 (d, J = 14.5 Hz, 8H), 3.07 (dq, J = 13.8, 6.8, 
6.7, 6.7 Hz, 1H), 2.92 (dq, J = 14.1, 6.7, 6.6, 6.6 Hz, 1H), 2.42 (s, 3H), 2.23 (s, 2H), 1.87 (dt, J = 
15.6, 7.5, 7.5 Hz, 1H), 1.75 (s, 1H), 1.54 (dt, J = 15.8, 7.1, 7.1 Hz, 1H). MS-ESI (m/z): [M + H]
+
 
calcd for C49H47ClN12O4S 935.3325; found 935.3330.  
 
Spectral Data for Compounds 
 Spectral data (
1
H NMR) for compounds are shown in Appendix C. 
 
General Biochemical Methods 
 Black, opaque-bottom 96 well plates were purchased from Nunc. All proteins were 
expressed in E.coli using previously published procedures.
25
 Data were obtained using Biotek 




Determination of Inhibitor IC50 Values against 3D c-Abl. 
 A continuous fluorescence assay was used to determine IC50. The reaction volume was 
100 μL consisting of 85 μL of enzyme in buffer, 2.5 μL of the appropriate inhibitor dilution 
(typically 3333.33, 1111.11, 370.37, 123.46, 41.15, 13.72, 4.57, 1.52, 0.507, and 0 µM in 
DMSO), and 2.5 μL (2.4 mM in DMSO) of a substrate peptide.
26
 The reaction was initiated with 
10 μL of ATP (50 mM in water unless otherwise noted), and reaction progress was immediately 
monitored at 405 nm (ex. 340 nm) for 10 minutes. Reactions had final concentrations of 30 nM 
enzyme (unless otherwise noted), 60 μM peptide substrate, 5 mM ATP, 100 μM Na3VO4, 100 
mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-100. The initial rate data collected was 
used for determination of IC50 values. For IC50 determination, the kinetic values were obtained 
directly from nonlinear regression of substrate-velocity curves in the presence of various 
concentrations of the inhibitor. The equation Y = Bottom + (Top – Bottom)/(1 + 10^X – 
LogEC50), X = log(concentration) and Y = binding; was used in the nonlinear regression. An 
IC50 value was determined for each inhibitor using at least two independent experiments (unless 
otherwise noted). The individual IC50 values for the two runs were then averaged. A 
representative inhibition curve of a single run is shown in Appendix C. 
 
General procedure for cellular characterization. 
1. Cell culture and seeding: All Ba/F3 cell lines were cultured in RPMI 1640 media with 10% 
FBS. Parental Ba/F3 cell culture additionally contained 15% WEHI-3 conditioned media. An 
aliquot of the cells was mixed with Trypan Blue solution and the cell number was quantified 
using a hemocytometer. The cells were plated 100 μL in each well at 30,000 cells/mL so that 
each well contained 3,000 cells. The cells were plated into sterile, clear bottom 96 well plates 
and then immediately dosed with compound. Additionally, 3 wells were created containing 100 
μL of media with no cells. 
2. Dosing: The compounds were made in 100% DMSO at 1,000X the final concentrations that 
were desired for the assay generally covering a concentration range of 6 log units. These DMSO 
stocks were diluted 10X in RPMI 1640 media. 1 μL of the compound diluted in media was added 
to each well for a final concentration of 0.1% DMSO. The wells containing only media were not 
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dosed. In general, each compound concentration was dosed in triplicate wells. The plates were 
returned to normal culture conditions (per ATCC) for 72 hours. 
3. Assay: After 72 hours, the plates were removed from the incubator, and 10 μL of WST-1 
reagent was added to each well. The plates were returned to the incubator and the color change 
was visually monitored for 0.5 – 2 hours. When sufficient color change had occurred, the plates 
were shaken on a plate shaker for 30 seconds, and absorbance at 450 and 630 nm was read in a 
Biotek Synergy 4 plate reader. The absorbance at 630 nm was subtracted from the absorbance at 
450 nm. 
4. Data Analyses: The average absorbance value from wells containing media without cells was 
subtracted from the absorbance value for all the wells containing cells. The absorbance values 
were then taken as a percentage of the absorbance for the vehicle wells (0.1% DMSO - no 
compound). The percent compared to vehicle was then plotted vs. log(Concentration). Data 
analyses and curve fitting were performed using Graphpad Prism 6. For each compound, there 
were n = 3 data points for each concentration. For curves that did not reach full inhibition, the 
bottom was set to -10. The curves with error bars are shown in Appendix C. 
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Synergy between Allosteric and Active Site Inhibitors of c-Abl Tyrosine Kinase 
 
Abstract 
 We investigated synergy between ATP-competitive inhibitors of c-Abl and the allosteric 
inhibitor GNF-2. We have found that inhibitors that bind in different conformations in the ATP-
binding site can cause a change in the global conformation of c-Abl. GNF-2, which binds c-Abl 
in a closed conformation, is only synergistic with ATP-competitive inhibitors that bind the same 
conformation. Since no approved ATP-competitive inhibitors bind a closed conformation, we 
turned to an αC-helix-out inhibitor of c-Abl recently developed (Das-CHO-II) in our lab. When 
combined, GNF-2 and Das-CHO-II were highly synergistic in BCR-Abl Ba/F3 cells as well as 
K562 cells. Furthermore, this combination resulted in a 1000X improvement in the GI50 of Das-
CHO-II. Additionally, the synergy seen between GNF-2 and Das-CHO-II was capable of 
overcoming the common, T315I clinical mutation. 
 
Introduction 
 Fusion protein BCR-Abl caused by the translocation of chromosomes 19 and 22 is the 
causative factor in Chronic Myelogenous Leukemia (CML).
1
 The ATP-competitive c-Abl 
inhibitor imatinib is very effective in increasing CML patient survival.
2
 Unfortunately, over time, 
many patients develop resistance to imatinib and several second-generation BCR-Abl inhibitors.
3
 
This occurs due to a common point mutation, T315I. Third-generation BCR-Abl inhibitor 
ponatinib is the only approved inhibitor for the T315I mutation of BCR-Abl; however, it carries 
a black box warning for causing "adverse vascular events" in 48 percent of patients.
4
 Since 
patients who develop CML are typically over 60 years of age often with existing heart 
conditions,
5
 the use of ponatinib is undesirable in these patients. Thus, novel strategies to combat 
the T315I mutation are critical. 
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 As mentioned in Chapter IV, an allosteric inhibitor of c-Abl, GNF-2, was discovered in 
an attempt to combat resistance.
6
 Both NMR and crystallographic data indicate that GNF-2 binds 
in the myristate pocket of c-Abl.
7,8
 The myristate pocket is located within the kinase domain of 
c-Abl and serves as a means of autoregulation. c-Abl is inactivated when its myristoylated, N-
terminal tail tucks itself inside the previously mentioned myristate pocket.
9
 This kinks the I-helix 
in the kinase domain, which provides a docking site for the SH2 domain of c-Abl. The docking 
of the SH2 domain to the kinase domain of c-Abl causes the linker between the kinase domain 
and the SH2 domain to coil. The SH3 domain then clamps down on this coiled linker, which 
reorients the N and C-lobes of the kinase domain rendering it inactive. Crystallographic data has 
shown that GNF-2 causes a similar kinking of the I-helix when bound in the myristate pocket.
8
 
This suggests that the binding of GNF-2 engages the SH2 and SH3 domains, inhibiting the 
kinase domain. 
 Since its discovery, there has been a strong interest in combining GNF-2 with ATP-
competitive inhibitors with the idea that the combination would be synergistic and also slow the 
development of resistance, including the T315I mutation.
8
 Many groups have shown synergy 
between GNF-2 and various ATP-competitive inhibitors.
7,8,10
 There have been, however, 
contradictory reports suggesting that these combinations are actually not synergistic.
11
 
Furthermore, it has been shown that both imatinib and GNF-2 affect the global structure of c-
Abl; however, they cause c-Abl to adopt slightly different conformations.
12
 With these data in 
mind, we decided to further investigate the relationship between ATP-competitive inhibitors and 
GNF-2.  
 
Synergy of ATP-Competitive Compounds with GNF-2 
 As stated, there are several conflicting claims as to whether or not current ATP-
competitive inhibitors demonstrate synergy in c-Abl when combined with GNF-2.
8,11
 We 
decided to perform an analysis of combinations between GNF-2 and four approved ATP-
competitive inhibitors of c-Abl (dasatinib, imatinib, nilotinib, and ponatinib). Using the Chou-
Talalay method, 
13,14
 we determined the combination indices (CI) for these four combinations in 
BCR-Abl Ba/F3 cells. The Chou-Talalay method is based upon the median effect principle of the 
mass action law.
15
 To determine a CI value between two drugs, the effect of each drug upon cell 
growth at varying concentrations is determined. Then, the effect of the two together at varying 
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concentrations of both is determined. The doses and corresponding cell growth effect data are 
entered into the CompuSyn computer program, which determines the CI using equation (1) in 
Appendix D.
15
 A CI <1 is synergistic, CI = 1 is additive, and CI >1 is antagonistic. As shown in 
Table 5.1, we found that none of the inhibitors tested demonstrated synergy. This was in sharp 
contrast to several previous reports.
7,8,10
 Given their unique binding sites, we hypothesized that 
both GNF-2 and ATP-competitive inhibitors should be able to bind simultaneously and would 
thus show synergy. With these results in hand, we decided to investigate why these inhibitors did 
not show synergy. This led us to a deeper structural investigation of the binding modes of these 
inhibitors. 
Table 5.1. Combination Indices for various ATP-competitive inhibitors with GNF-2 
ATP-Competitive Inhibitor CI50 CI75 CI90 CI95 
dasatinib 0.84 0.93 1.04 1.12 
imatinib 0.88 0.87 0.87 0.87 
nilotinib 0.94 0.94 0.94 0.94 
ponatinib 1.02 1.02 1.02 1.02 
 
 
Evaluating c-Abl Global Conformation 
 c-Abl activity is carefully regulated in cells by auto-inhibition. In its inactive state, the 
kinase adopts a compact "closed" conformation in which the SH2 and SH3 domains "clamp 
down" on the kinase domain, inhibiting activity.
9
 When activated, the kinase adopts an "open" 
conformation where the structure becomes more elongated and the SH2 domain moves to a "top-
hat" location on top of the N-lobe of the kinase domain.
16,17
 One of the biggest hallmarks of the 
open vs. closed conformations is whether the linker between the kinase domain and SH2 domain 
is exposed. WT c-Abl, when not down-regulated, is seen in the "top-hat" conformation where the 
linker is exposed.
16,17
 In SH3 engaged Abl (Abl HAL9), a highly "closed" c-Abl construct, the 
linker is protected.
18
 Mutants, such as A337N, have been shown to be even more active than 
wild-type, implying a more open conformation.
19
  
 Our lab has developed a protease accessibility assay to assess these different global 
conformations of kinases based on the accessibility of the linker between the kinase and SH2 
domains. It is simple, low cost, and medium throughput. The protease thermolysin is known to 
cleave several kinases at a site on the linker (unpublished data by Michael P. Agius). Cleavage of 
the kinase over time by thermolysin can be evaluated by measuring the intensity of the full-
length protein via SDS-PAGE. The band intensity can then be plotted vs. time to obtain a half-
life curve. A construct that is more open will have a more exposed linker, be proteolyzed more 
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quickly by thermolysin, and thus have a shorter half-life (Figure 5.1). We used the constructs 






















Figure 5.1. Open (A337N Abl), WT, and closed (SH3 Engaged Abl) controls for the protease accessibility assay 
visualized as (a) disappearance of the protein band and (b) corresponding half-live decay curves.  
 
Inhibitor Effect on c-Abl Global Conformation  
 After verifying the proteolysis assay using established c-Abl constructs, we used the 
assay to analyze each drug tested in combination with GNF-2. To more easily visualize the 
compounds that stabilized the open vs. closed conformation, we represented the data as log( T1/2 / 
WT Abl T1/2) so that Wild Type Abl would be represented by zero, the closed conformation 
would be represented by values greater than zero, and the open conformation would be 
represented by values less than zero. We observed (Figure 5.2) that all four ATP-competitive 
inhibitors stabilized the open conformation of c-Abl, even more so than the A337N mutant. 
GNF-2 resulted in a closed conformation of c-Abl, similar to SH3 engaged. We contend that the 
lack of synergy between GNF-2 and the tested ATP-competitive inhibitors was due to the fact 










Figure 5.2. Effect of ATP-competitive inhibitors and GNF-2 upon WT Abl conformation shown as both (a) 
proteolysis half-lives and (b) percent closed 
 
Evaluating αC-helix-out Inhibitors 
 Once the global conformation for all these inhibitors was determined, we realized that the 
best inhibitor to potentially combine with GNF-2 would be an ATP-competitive inhibitor that 
bound a closed conformation of c-Abl. αC-helix-out (CHO) inhibitors are known to bind the 
closed conformation of kinases. We decided to use a CHO inhibitor developed in our lab as part 
of a "matched set" of kinase inhibitors created by Kristoffer Brandvold, Sameer Phadke, and 
Frank Kwarcinski.
20
 This set of inhibitors is based on a dasatinib scaffold and contains two CHO 
inhibitors (Das-CHO-I and Das-CHO-II) and two DFG-out (Type II) inhibitors (Das-DFGO-I 
and Das-DFGO-II). Since Das-CHO-II is more than ten times more potent than Das-CHO-I, we 
decided to utilize Das-CHO-II to assess our hypothesis. First, the global conformation that Das-
CHO-II adopted was determined. As shown in Figure 5.3, compared to apo c-Abl, Das-CHO-II 
stabilized a more closed conformation. We also tested Das-DFGO-II and were unsurprised to see 
that it opened c-Abl to the same degree as other Type II c-Abl inhibitors (nilotinib, imatinib, and 
ponatinib). We also wanted to assess the three known kinase conformation selective inhibitors in 
combination with GNF-2 to see how those combinations may affect global conformation. We 
found that the combination of a Das-DFGO-II and GNF-2 was still more open than apo c-Abl 
indicating an ineffective combination. The combination of dasatinib (a Type-I inhibitor) and 
GNF-2 was slightly closed but overall, similar to the apo enzyme. Gratifyingly, though, the 
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combination of Das-CHO-II and GNF-2 was closed, even more so than the highly closed SH3 
engaged c-Abl. These data were encouraging, and we hypothesized that Das-CHO-II and GNF-2 









Figure 5.3. Conformation of WT Abl with (a) the conformation selective inhibitors and (b) combinations of the 
conformation selective inhibitors with GNF-2 
 
Combining Das-CHO-II and GNF-2 
 We decided to further evaluate the combination of Das-CHO-II with GNF-2. We 
evaluated synergy as before, and in conformation of our hypothesis, the combination was 
observed to be highly synergistic with a CI50 of 0.23. An analog of GNF-2
21
 was also determined 
to be synergistic with a CI50 of 0.66 (Appendix D). GNF-2 and Das-CHO-II are not 
exceptionally potent in cells compared to other c-Abl inhibitors (GI50 (both) ≈ 500nM); however, 
we wanted to see how the synergy between the two could be used to leverage potency against 
BCR-Abl Ba/F3 cells. First, we evaluated the GI50 of GNF-2 with the addition of a constant, sub-
GI50 concentration (100 nM) of Das-CHO-II. This lead to a dramatic decrease in the GI50 of 
GNF-2 to 17nM (Figure 5.4). The results for Das-CHO-II were even more striking. When 
combined with 200 nM of GNF-2, we observed a 1,000 fold improvement in the GI50 of Das-
CHO-II from 550 nM to 0.55 nM (Table 5.2). 
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Figure 5.4. GI50 curves for GNF-2, Das-CHO-II, GNF-2 + 100 nM Das-CHO-II, and Das-CHO-II + 200 nM GNF-2 
in BCR-Abl Ba/F3 cells illustrating the magnitude of improvement realized by the combination of Das-CHO-II and 
GNF-2 
 
 The comparison of a compound's GI50 in BCR-Abl Ba/F3 and Parental Ba/F3 cells that 
do not overexpress BCR-Abl is a common measure of the therapeutic index. By combining the 
two agents, we were able to significantly increase the therapeutic index. In Parental Ba/F3 cells, 
GNF-2 did not inhibit cell growth up to 10 μM, and Das-CHO-II had a GI50 of 2.8 μM, giving 
them therapeutic indices of  >22 and 5.2, respectively (Table 5.2). Combining the two agents did 
very little to change the GI50 values in Parental Ba/F3 cells. The combination of GNF-2 with 100 
nM Das-CHO-II still did not inhibit cell growth up to 10 μM, and the combination of Das-CHO-
II with 200 nM GNF-2 had a GI50 of 1.5 μM. These combinations now gave respective 
therapeutic indices of >590 and 2,800 (Table 5.2). 
 
Table 5.2. GI50 values for GNF-2, Das-CHO-II, GNF-2 + 100 nM Das-CHO-II, and Das-CHO-II + 200 nM GNF-2 
in both BCR-Abl Ba/F3 and Parental Ba/F3 cells demonstrating improvements in potency and therapeutic index 








GNF-2 450  >10,000 >22 
Das-CHO-II 550  2,800 5 
GNF-2 + 100 nM Das-CHO-II 17 26X >10,000 >590 
Das-CHO-II + 200 nM GNF-2 0.55 1000X 1,500 2,700 
 
 
 These data are exciting; however, Ba/F3 cell lines are stably transfected, murine cells, so 
we wanted to test the combination of GNF-2 and Das-CHO-II in a human CML cell line. We 
tested for synergy between the two in K562 cells along with constant concentration 
combinations. Gratifyingly, we observed both synergy and an improvement in potency. In K562, 
the CI50 was 0.47 and the GI50 of both GNF-2 and Das-CHO-II increased approximately 4 fold 
when combined with a constant concentration (GI50) of the other (Table 5.3). Finally, using 
-II 
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previously synthesized BODIPY-labeled analogs of our Type II and CHO inhibitors, termed 
Das-DFGO-II-BODIPY and Das-CHO-II-BODIPY,
20
 respectively, we investigated the effect of 
GNF-2 on the EC50 of the two probes. As expected, the EC50 of Das-CHO-II-BODIPY improved 
with 1 μM GNF-2 while the EC50 of Das-DFGO-II-BODIPY remained relatively unchanged 
(Appendix D).  
Table 5.3. GI50 Values of GNF-2, Das-CHO-II, GNF-2 + 65 nM Das-CHO-II, and Das-CHO-II + 800 nM GNF-2 in 
K562 cells demonstrating an improvement in potency when combined. 
 GI50 (nM) Improvement in Potency 
GNF-2 808  
Das-CHO-II 64  
GNF-2 + 65 nM Das-CHO-II 215 4X 
Das-CHO-I + 800 nM GNF-2 16 4X 
 
 
Overcoming GNF-2 Resistance Mutants 
 We sought to understand why GNF-2 cannot bind to mutant forms of Abl where the 
mutation is at a site distinct from the myristate-binding site. We first evaluated several mutants 
reported in the literature that are not present in the myristate pocket but are resistant to GNF-2 
inhibition: P112S, S229P, and the clinical mutation T315I.
8
 We evaluated GNF-2 in a continuous 
activity assay
22
 with each  mutant and found that GNF-2 could not inhibit any of them 
(Appendix D). Since they do not cause GNF-2 resistance due to steric occlusion, we 
hypothesized that these mutants cause c-Abl to adopt an open conformation, while GNF-2 binds 
a closed conformation. We first evaluated each mutant using the protease assay. Gratifyingly, 
every mutant caused the kinase to adopt an open conformation (Figure 5.5). A separate report 
has validated our finding that T315I Abl adopted a more open conformation than wild-type.
23
 
Our findings now provided a rationale as to why GNF-2 cannot bind other mutations that occur 







Figure 5.5. GNF-2 resistant mutants. (a) Mutants that show resistance to GNF-2 both in the myristate pocket (lower 
right) and distal sites
8
 (b) The open conformation of the distal mutants shown in comparison to the A337N open 
conformation, apo c-Abl, and SH3 engaged closed conformation controls. 
  
 Given its clinical importance, we decided to focus the rest of our efforts on T315I Abl. 
We wanted to investigate whether the combination of GNF-2 and Das-CHO might affect the 
global conformation of T315I. We found that both inhibitors alone closed T315I slightly; 
however, they were still more open than wild-type Abl. The combination of the two, however, 
was capable of closing T315I to a level more closed than wild-type c-Abl. We then hypothesized 
that the combination of the GNF-2 and Das-CHO-II would be capable of overcoming T315I 
resistance in T315I Abl Ba/F3 cells. 
 
Figure 5.6. Global conformation of GNF-2, Das-CHO-II, and a combination of the two in T315I Abl demonstrating 
that the combination changes the conformation of the T315I mutation while neither compound alone can. 
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 Alone, both compounds poorly inhibit T315I Abl Ba/F3 growth; GI50(GNF-2) > 10 μM 
and GI50(Das-CHO-II) = 3.2 μM (Table 5.4). Combining them, however, was far more effective. 
When added at a constant concentration below the GI50 (2 μM), the GI50 values for GNF-2 and 
Das-CHO-II improved remarkably, 1.8 μM and 127.9 nM, respectively. This 25 fold 
improvement for Das-CHO-II improved the therapeutic index against T315I Ba/F3 cells over 
Parental Ba/F3 cells from 0.9 to 22. Furthermore, when combined with GNF-2, the GI50 of Das-
CHO-II in T315I Abl Ba/F3 cells was even better than Das-CHO-II alone in BCR-Abl Ba/F3 
cells, which is truly remarkable. 
Table 5.4. GI50 Values for GNF-2, Das-CHO-II, GNF-2 + 2 μM Das-CHO-II, and Das-CHO-II + 2 μM GNF-2 in 
T315I Abl Ba/F3 cells that show the improvement in potency achieved when Das-CHO-II and GNF-2 are combined 
 GI50 (μM) Improvement in Potency 
GNF-2 >10  
Das-CHO-II 3.2  
GNF-2 + 2 μM Das-CHO-II 1.8 >5.6X 




 This chapter describes a better understanding of the interaction between allosteric and 
ATP-competitive inhibitors of c-Abl. Since the discovery of imatinib to treat CML, there has 
been a huge interest in the development of c-Abl inhibitors. There is a wealth of ATP-
competitive approved Abl inhibitors as well as a highly selective allosteric inhibitor, GNF-2. 
Using a newly developed protease accessibility assay, we evaluated the global conformation that 
these different inhibitors cause c-Abl to adopt. GNF-2 causes c-Abl to adopt a closed 
conformation, unlike any approved ATP-competitive inhibitors, which all cause an open 
conformation. We then turned to recently developed conformation selective inhibitors of c-Abl. 
Das-CHO-II binds c-Abl in an αC-helix-out conformation, which should close the kinase. We 
validated this using our protease assay. Gratifyingly, the conformation an inhibitor caused c-Abl 
to adopt, as determined using the protease assay, was directly related to synergy. GNF-2 did not 
show synergy with inhibitors that opened c-Abl and showed very strong synergy with inhibitors 
that closed it. We then evaluated how this synergy would play out in terms of cellular efficiency. 
The GI50 values for both GNF-2 and Das-CHO-II were determined in BCR-Abl Ba/F3 cells. 
Most remarkable was the fact that Das-CHO-II had a sub-nanomolar GI50 when combined with a 
constant, sub-GI50 concentration of GNF-2. This was incredibly exciting result. Furthermore, the 
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combination of Das-CHO-II and GNF-2 was able to overcome the common, clinical T315I 
mutation in cells even though both inhibitors were >2 μM inhibitors in T315I expressing Ba/F3 
cells alone. Not only did we discover a highly synergistic combination between an ATP-
competitive inhibitor and the allosteric c-Abl inhibitor GNF-2, we were also able to directly 
predict if a combination would show synergy based on the global conformation the inhibitor 
caused c-Abl to adopt, as determined by a protease accessibility assay. 
 
Materials and Methods 
 
General Biochemical Methods 
 Black, opaque-bottom 96 well plates were purchased from Nunc. All proteins were 
expressed in E.coli using previously published procedures.
24
 Data were obtained using Biotek 
Synergy Mx and Biotek Synergy 4 plate readers. Curve fitting was done using Graphpad Prism 6 
software. 
 
Determination of Inhibitor IC50 Values against 3D Abl. 
 A continuous fluorescence assay was used to determine IC50. The reaction volume was 
100 μL consisting of 85 μL of enzyme in buffer, 2.5 μL of the appropriate inhibitor dilution 
(typically 10000, 3333.33, 1111.11, 370.37, 123.46, 41.15, 13.72, 4.57, 1.52, and 0 µM in 
DMSO), and 2.5 μL (2.4 mM in DMSO) of a substrate peptide.
25
 The reaction was initiated with 
10 μL of ATP (50 mM in water unless otherwise noted), and reaction progress was immediately 
monitored at 405 nm (ex. 340 nm) for 10 minutes. Reactions had final concentrations of 30 nM 
enzyme (unless otherwise noted), 60 μM peptide substrate, 5 mM ATP, 100 μM Na3VO4, 100 
mM Tris buffer (pH 8), 10 mM MgCl2, 0.01% Triton X-100. The initial rate data collected was 
used for determination of IC50 values. For IC50 determination, the kinetic values were obtained 
directly from nonlinear regression of substrate-velocity curves in the presence of various 
concentrations of the inhibitor. The equation Y = Bottom + (Top – Bottom)/(1 + 10^X – 
LogEC50), X = log(concentration) and Y = binding; was used in the nonlinear regression. An IC50 
value was determined for each inhibitor using at least three independent experiments (unless otherwise 
noted). The individual IC50 values for the three runs were then averaged. A representative inhibition curve 
of a single run is shown in Appendix D. 
76 
 
General procedure for BODIPY probe EC50 determination. 
 A fluorescence polarization was used to determine EC50 values. Reaction volumes of 50 
μL were used in 96-well plates. 34 μL of buffer (50 mM Tris buffer (pH 8), 10 mM NaCl, 5% 
Glycerol, 1 mM DTT) was added to a single row, followed by 15 μL of enzyme (3.3X 
concentration) in buffer with 2-fold dilutions (typically 150, 75, 37.5, 18.75, 9.375, 4.69, 2.34, 
1.17, 0.586, 0.293, and 0 nM final well concentration). Then, 1 μL of a 500 nM stock of the 
appropriate dasatinib analog BODIPY probe in DMSO was added (2% DMSO final). Wells were 
incubated on ice for 30 minutes prior to fluorescence polarization read (ex/em 485/535 nm). 
After the initial read, 1 μL of 51 μM GNF-2 was added to each well for a final concentration of 1 
μM GNF-2. Following another 30 minute incubation on ice, the wells were read again. Reactions 
had final concentrations of 10 nM BODIPY-probe, 50 mM Tris buffer (pH 8), 10 mM NaCl, 5% 
Glycerol, 1 mM DTT. For Kd determination, the mPolarization values (normalized to the 0 nM 
protein control) were plotted vs. varying protein concentrations. The equation Y = (Bmax * 
X)/(EC50 + X), X = Protein concentration and Y = FP response; was used in the nonlinear 
regression. In two separate runs, the EC50 value was determined using at least four independent 
experiments. The EC50 value determined from the two separate runs was averaged. A single 
representative inhibition curve with error bars is shown in Appendix D. 
 
General Procedure for Proteolysis Half-Life Determination 
 c-Abl was diluted in proteolysis buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.5 mM 
CaCl2) to yield a final protein concentration of 2 µM. This was followed by the addition 1 μL of 
a 10 mM stock of each compound being tested to give a final concentration of 57 μM compound. 
15 µL of the protein/compound solution was added to 5 µL of 50 mM EDTA as the 0 min time 
point. The proteolysis reaction was initiated by adding Thermolysin (purchased from Promega, 
catalog number: V4001) from a 3.8 μM stock solution to a final concentration of 50 nM. At 
various time points (2, 5, 10, 30, 60, 90, 120, 180, and 240 mins), 15 µL of the proteolysis 
reaction was added to 5 µL of 50 mM EDTA to quench proteolysis. The quenched samples were 
analyzed by SDS-PAGE (12 % Bis-Tris gel in MES running buffer, staining with coomassie 
blue). Band intensities were analyzed by ImageJ imaging software. Percent protein remaining 
was plotted against time and fit to an exponential decay equation using GraphPad Prism software 
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to obtain half-lives of each protein. Each half-life was determined using a single experiment, 
with the exception of WT Abl in order to demonstrate assay reproducibility. The half-life curves 
are shown along with the gel for each apo protein (Appendix D).  
 
General procedure for cellular characterization. 
1. Cell culture and seeding: All Ba/F3 and K562 cell lines were cultured in RPMI 1640 media 
with 10% FBS. Parental Ba/F3 cell culture additionally contained 15% WEHI-3 conditioned 
media. An aliquot of the cells was mixed with Trypan Blue solution and the cell number was 
quantified using a hemocytometer. The cells were plated 100 μL in each well at 30,000 cells/mL 
so that each well contained 3,000 cells. The cells were plated into sterile, clear bottom 96 well 
plates and then immediately dosed with compound. Additionally, 3 wells were created 
containing 100 μL of media with no cells. 
2. Dosing: The compounds were made in 100% DMSO at 1,000X the final concentrations that 
were desired for the assay generally covering a concentration range of 6 log units. These DMSO 
stocks were diluted 10X in RPMI 1640 media. 1 μL of the compound diluted in media was added 
to each well for a final concentration of 0.1% DMSO. The wells containing only media were not 
dosed. In general, each compound concentration was dosed in triplicate wells. The plates were 
returned to normal culture conditions (per ATCC) for 72 hours. 
3. Assay: After 72 hours, the plates were removed from the incubator, and 10 μL of WST-1 
reagent was added to each well. The plates were returned to the incubator and the color change 
was visually monitored for 0.5 – 2 hours. When sufficient color change had occurred, the plates 
were shaken on a plate shaker for 30 seconds, and absorbance at 450 and 630 nm was read in a 
Biotek Synergy 4 plate reader. The absorbance at 630 nm was subtracted from the absorbance at 
450 nm. 
4. Data Analyses: The average absorbance value from wells containing media without cells was 
subtracted from the absorbance value for all the wells containing cells. The absorbance values 
were then taken as a percentage of the absorbance for the vehicle wells (0.1% DMSO - no 
compound). The percent compared to vehicle was then plotted vs. log(Concentration). Data 
analyses and curve fitting were performed using Graphpad Prism 6. For each compound, there 
were n = 3 data points for each concentration. For curves that did not reach full inhibition, the 
bottom was set to -10. The curves with error bars are shown in Appendix D. 
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General procedure for cellular synergy. 
1. Cell culture and seeding: All Ba/F3 and K562 cell lines were cultured in RPMI 1640 media 
with 10% FBS. Parental Ba/F3 cell culture additionally contained 15% WEHI-3 conditioned 
media. An aliquot of the cells was mixed with trypan blue solution and the cell number was 
quantified using a hemacytometer. The cells were plated 100 μL in each well at 30,000 cells/mL 
so that each well contained 3,000 cells. The cells were plated into sterile, clear bottom 96 well 
plates and then immediately dosed with compound. 
2. Dosing: The compounds dilutions (2X) and combinations were made in 100% DMSO at 
1,000X the final concentrations that were desired for the assay. These DMSO stocks were diluted 
10X in RPMI 1640 media. 1 μL of the compound diluted in media was added to each well for a 
final concentration of 0.1% DMSO. The wells containing only media were not dosed. In general, 
each compound concentration was dosed in triplicate wells. The plates were returned to normal 
culture conditions (per ATCC) for 72 hours. 
3. Assay: After 72 hours, the plates were removed from the incubator and 10 μL of WST-1 
reagent was added to each well. The plates were returned to the incubator and the color change 
was visually monitored for 0.5 – 2 hours. When sufficient color change had occurred, the plates 
were shaken on a plate shaker for 60 seconds and read in a Biotek Synergy 4 plate reader. 
4. Data Analyses: The average absorbance value from wells containing media without cells was 
subtracted from the absorbance value for all the wells containing cells. The data were then 
calculated as a fraction of the vehicle well (1% DMSO) and subtracted from 1 in order to 
represent the data as the fraction of population affected by the treatment at each given dose. The 
data were then analyzed using Compusyn to determine the combination indices. The curves and 
isobolograms are shown in Appendix D. 
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Conclusions and Future Directions 
 
Abstract 
 Kinases are a important enzymes for transmitting cellular signals. Kinase inhibitors have 
worked successfully as drugs and tools to understand kinase signaling in cells. Most kinase 
inhibitors, however, bind in the conserved ATP-binding pocket often rendering them 
promiscuous. To create more selective inhibitors, we explored kinase inhibitors that interacted 
with other sites of the kinase. This was a successful strategy for creating selective kinase 
inhibitors. Most importantly, though, we learned about the important role that the global 
conformation of a kinase plays. Furthermore, some inhibitors, even ones that only bind in the 
conserved ATP-binding pocket, are capable of modulating kinase global conformation. This has 
important implications involving potential synergy between inhibitors, especially in cells. 
 
Bivalent Inhibitors of Protein Tyrosine Kinases 
 Bivalent inhibitors are inhibitors capable of binding two sites of a protein simultaneously. 
They have the advantage of being more potent and selective than a single binding site inhibitor. 
In Chapters II and IV, we created bivalent inhibitors of the protein tyrosine kinases c-Src and c-
Abl, respectively. We used a modular strategy where the two binding pieces were conjugated 
using azide-alkyne click chemistry. We synthesized several ATP-competitive inhibitors with 
pendant alkynes that could be conjugated to several non-ATP-binding pocket molecules with 
pendant azides. In this way, we could mix the pieces accordingly to create several different 
bivalent inhibitors with different properties.  
 In c-Src, we began by conjugating a promiscuous amino-pyrazole to an optimal c-Src 
SH2 peptide to create bivalent inhibitor 2.3. The bivalent inhibitor was designed such that the 
linker would be too short to reach between the two binding sites when the kinase was in a closed, 
autoinhibited state. The linker was only long enough when the kinase was in an open, more 
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flexible conformation. Bivalent inhibitor 2.3 was 18X more potent than either binding portion 
alone in full length c-Src and 25X more potent for c-Src than a homologous kinase c-Abl, which 
optimally binds a different SH2 peptide than c-Src. Most interesting, however, was the fact that 
bivalent inhibitor 2.3 was also selective for c-Src over other Src family kinases (SKFs) which 
bind the same optimal SH2 peptide.
1,2
 This further verified the idea that the global conformation 
of the kinase plays a role in inhibitor binding. Our bivalent inhibitor was specifically designed to 
bind the open, flexible conformation of c-Src. Not surprisingly then, the only SFK that bound 
bivalent inhibitor 2.3 with less than micromolar affinity was Fyn1, which other research has 
shown to be more flexible than other SFKs.
3
 
 For the bivalent inhibitor of c-Abl, we used the dasatinib-cyclooctyne as the ATP-binding 
portion of our bivalent inhibitor. We chose dasatinib-cyclooctyne because it is a dual c-Src/c-Abl 
inhibitor, and we wanted to demonstrate how a bivalent strategy could turn a dual inhibitor into 
one specific for a single target. GNF-2, an allosteric inhibitor that is uniquely selective to c-Abl, 
was conjugated to create bivalent inhibitor 4.2. This inhibitor was too potent to be fully 
evaluated using our continuous activity assay.
4
 We then used the services provided by Luceome 
Biotechnologies to determine IC50 values for 4.2 in full-length and kinase domain c-Abl, as well 
of full-length c-Src. We found that 4.2 was 10X more potent for full-length c-Abl, which further 
shows the effect that kinase global conformation has on inhibitor binding. It was also 25X more 
potent for c-Abl than c-Src validating our hypothesis that we could transform a dual c-Src/c-Abl 
inhibitor into an inhibitor specific for c-Abl. Furthermore, this bivalent inhibitor was cell 
permeable, and can be used as a selective inhibitor for c-Abl in cells.  
 Both bivalent inhibitors should be further investigated in cells. Inhibitor 4.2 is cell 
permeable so we could immediately begin more in-depth cellular assays; however, we would 
have to create a cell permeable version of 2.3. Bivalent inhibitor 2.3 is likely not cell permeable 
due to the anionic nature of peptide 2.2. This could be rectified by appending a cell-
permeabilizing peptide to 2.2. Our lab has successfully used a nona-arginine tail to create cell 
permeable, bivalent inhibitors.
5,6
 Since our bivalent inhibitors interact with sites outside the 
ATP-binding pocket (where most kinase inhibitors bind), it would be interesting to see how the 
down-stream signaling effects are different from ATP-competitive inhibitors. For example, the 
SH2 domain in c-Src is important for substrate recognition and scaffolding. As such, by binding 
the SH2 domain as well as the ATP-binding pocket, I think we would observe different 
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downstream effects. For example, c-Src inhibits prolactin (PLR) induced mitogenesis by 
inhibiting Jak2 phosphorylation; however, pharmacological inhibition of c-Src does not affect 
Jak2 signaling.
7
 Furthermore, a construct of c-Src without the kinase domain containing only the 
SH2 and SH3 domains was still capable of inhibiting PLR-induced Jak2 phosphorylation 
suggesting that the scaffolding functions, not the catalytic function of c-Src, were the driving 
force in this interaction.
8
 I hypothesize that a cell permeable version of 2.3 would 
pharmacologically validate these findings. As such, more in-depth cellular studies with 2.3 and 
4.2 should be performed.  
 
Allosteric Modulator of c-Src Kinase 
 Chapter III highlights our work to identify an allosteric modulator of c-Src capable of 
altering the global conformation of the kinase. Using a thermal shift assay, we screened a 1,000 
compound library from Maybridge for binding to full-length c-Src. It was very important to use 
full-length c-Src since we desired a compound that would affect global conformation. We 
defined hits as compounds that changed the Tm of c-Src by greater than three standard 
deviations from the negative control. Using these parameters, we identified 37 hits (~4% hit 
rate). We then used a protease accessibility assay to determine how these compounds affected 
the global conformation of c-Src. Of the 37 hits, we decided to only pursue the two that caused 
the greatest change in c-Src global conformation (both adopted a more open conformation). We 
then tested the effect of these hits upon c-Src activity using a continuous activity assay.
4
 One had 
no effect upon c-Src activity; however, the other (1-E8) proved to be an activator of c-Src. This 
confirmed our hypothesis that the global conformation a small molecule stabilized in a kinase 
would affect catalytic activity correspondingly. 
 We then wanted to establish a general binding site for activator 1-E8. We first 
determined that 1-E8 has no activity against pY527 (the phosphotyrosine responsible for the 
closed, autoinhibited conformation of c-Src). This suggested that 1-E8 binds somewhere 
inaccessible in the closed conformation of c-Src, possibly the linker region. We also found that 
1-E8 has no activity when competing with a pFAK peptide.
9
 Furthermore, it causes a significant 
increase in the EC50 of Src SH2 peptide 2.21. Taken together, these data suggest that 1-E8 binds 
in or near the SH2 domain of c-Src. 
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 We established that activator 1-E8 was selective for c-Src compared to two homologous 
kinases, c-Abl and Hck. 1-E8 has essentially no effect upon the activity of either. Since both 
possess an SH2 domain and Hck recognizes the same optimal peptide sequence as c-Src, it seems 
likely that the effect of 1-E8 is unique to the global conformation of c-Src. This continues to 
demonstrate the importance global conformation plays in inhibitor binding. With a selective c-
Src modulator, we wanted to see what effect we would observe in c-Src dependent cells. In HT-
29 cells, 1-E8 did not inhibit cell growth at concentrations up to 10 μM. When added to an 
inhibitor also known to bind an open conformation, however, the GI50 of that inhibitor improved 
twofold. We believe that 1-E8 was able to stabilize an open conformation of c-Src that allowed 
the other inhibitor to bind more easily and better inhibit the growth of c-Src dependent cells. 
 Since our data demonstrate that 1-E8 decreases the binding affinity of c-Src SH2 domain 
peptide 2.21, there is a possibility that it binds in the same location as 2.21.  If that were the case, 
it would be interesting to create an analog of c-Src bivalent inhibitor 2.3 using 1-E8 instead of 
2.2. This would create a non-peptidic, bivalent inhibitor of c-Src. Given that bivalent inhibitor 
4.2, which utilizes the same linker, is cell permeable, it would feasible that a bivalent inhibitor 
composed of 1-E8 and 2.1 would also be cell permeable. This would eliminate the need for the 
cell-permeabilizing peptides described above. As such, this proposed, small molecule bivalent 
inhibitor could be utilized in cells in the same manner described above. 
 
Synergy between Allosteric and Orthosteric Inhibitors 
 Our work in Chapter V provides an in-depth investigation into the interplay between 
allosteric and active-site inhibitors and how the global conformation that a kinase adopts greatly 
affects this interaction. Specifically, we focused on the allosteric inhibitor of c-Abl, GNF-2, and 
various approved and non-approved ATP-competitive inhibitors. We started by using the Chou-
Talalay method in BCR-Abl Ba/F3 cells to evaluate synergy between GNF-2 and dasatinib, 
nilotinib, imatinib, and ponatinib.
10,11
 Contrary to reported results,
12
 none of these inhibitors 
showed synergy with GNF-2. Using the same protease accessibility assay mentioned previously, 
we then assessed the conformation that each of these inhibitors stabilized in c-Abl. GNF-2 bound 
a closed conformation in c-Abl while every ATP-competitive inhibitor bound a very open 
conformation. We then hypothesized that only an ATP-competitive inhibitor that bound a closed 
conformation in c-Abl would show synergy with GNF-2. 
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 We then demonstrated that a αC-helix-out inhibitor developed in our lab (Das-CHO-II),
13
 
stabilized a closed c-Abl conformation. As expected, it was the only ATP-competitive inhibitor 
to show synergy with GNF-2. Furthermore, combining the two agents caused drastic 
improvements in their cellular GI50 values. The GI50 for Das-CHO-II in BCR-Abl Ba/F3 cells 
improved 1000X when a constant, sub-GI50 concentration of GNF-2 was added. This 
combination virtually no effect in Parental Ba/F3 cells giving a therapeutic index of 2,700. In a 
patient derived CML cell line, K562, we saw that adding a constant concentration (the GI50) of 
one compound (GNF-2 or Das-CHO-II) to the GI50 curve of the other resulted in a fourfold 
improvement in potency.  
 Additionally, GNF-2 has been combined with nilotinib in order to overcome the common 
and difficult to treat T315I clinical mutation.
12,14,15
 We did not observe synergy between the two 
inhibitors, so we wanted to see if a synergistic combination of would also overcome the T315I 
mutation. First, we evaluated the global conformation of T315I c-Abl and observed that it was 
much more open conformation than WT c-Abl, which would explain why GNF-2 cannot bind 
the T315I mutation despite the fact that the mutation occurs well away from the binding site of 
GNF-2. Next, we observed that the combination of GNF-2 and Das-CHO-II caused the T315I 
mutation to adopt a closed conformation when neither agent could alone. This was encouraging 
and prompted us to try combining Das-CHO-II and GNF-2 in T315I Abl Ba/F3 cells. Alone, 
GNF-2 showed no growth inhibition up to 10 μM and the GI50 for Das-CHO-II was 3.2 μM. 
When 2 μM of GNF-2 was added to the GI50 curve of Das-CHO-II, however, we observed a 25X 
improvement in growth inhibition. Through these experiments, we demonstrated the importance 
of the global conformation that a kinase inhibitor stabilizes. 
 This project has very important implications for drug combination therapy. Currently, 
Novartis is developing a combination therapy for CML using nilotinib and a GNF-2 analog.
16,17
 
We have shown, however, that nilotinib is not synergistic with GNF-2, and an αC-helix-out 
inhibitor was the only ATP-competitive inhibitor to show synergy with GNF-2. As such, a 
combination therapy between Das-CHO-II and GNF-2 has the potential to be even more 
successful. To move forward, the combination of Das-CHO-II and GNF-2 should be carried 
forward into animals. Besides its use in cells, the Chou-Talalay method can be utilized in 
animals to determine a synergistic combination, which would further validate the synergy seen in 
cells.
18
 In this case, we may want to investigate more analogs of Das-CHO-II and GNF-2. GNF-2 
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is already known to not have favorable PK properties; however, analogs are being developed.
12,17
 
Additionally, our lab is moving forward to develop more αC-helix-out inhibitors of c-Abl. 
 
Conclusions 
 We have demonstrated several strategies for targeting kinases outside of the ATP-binding 
pocket. We created bivalent inhibitors and discovered allosteric modulators. Both the bivalent 
and allosteric small molecules exploited the global conformation of the kinase they bound. 
Furthermore, we investigated the interplay between allosteric and active-site inhibitors. Knowing 
that inhibitor binding relies so heavily on kinase global conformation, we surprised that very 
little thought had previously been given to the global conformations inhibitors caused when 
trying to find synergistic combinations. We used a protease accessibility to determine kinase 
global conformation stabilized by small molecules and used it to predict combinations that would 
be synergistic. So often, kinase inhibitor discovery focuses on the kinase domain since that is 
where the catalytic action takes place, but we have shown that considerations about the global 
conformation are crucial. 
 
References 
(1)  Zhou, S.; Shoelson, S.; Chaudhuri, M.; Gish, G.; Pawson, T.; Haser, W.; King, F.; 
Roberts, T.; Ratnofsky, S.; Lechleider, R.; Neel, B.; Birge, R.; Fajardo, J.; Chou, M.; 
Hanafusa, H.; Schaffhausen, B.; Cantley, L. SH2 Domains Recognize Specific 
Phosphopeptide Sequences. Cell 1993, 72 (5), 767–778. 
(2)  Liu, B. A.; Jablonowski, K.; Shah, E. E.; Engelmann, B. W.; Jones, R. B.; Nash, P. D. 
SH2 Domains Recognize Contextual Peptide Sequence Information to Determine 
Selectivity. Mol. Cell. Proteomics 2010, 9, 2391–2404. 
(3)  Register, A. C.; Leonard, S. E.; Maly, D. J. SH2-Catalytic Domain Linker Heterogeneity 
Influences Allosteric Coupling across the SFK Family. Biochemistry 2014, 53 (44), 6910–
6923. 
(4)  Wang, Q.; Cahill, S. M.; Blumenstein, M.; Lawrence, D. S. Self-Reporting Fluorescent 
Substrates of Protein Tyrosine Kinases. J. Am. Chem. Soc. 2006, 128 (6), 1808–1809. 
(5)  Brandvold, K. R.; Santos, S. M.; Breen, M. E.; Lachacz, E. J.; Steffey, M. E.; Soellner, M. 
B. Exquisitely Specific Bisubstrate Inhibitors of c-Src Kinase. ACS Chem. Biol. 2015, 10, 
1387–1391. 
(6)  Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; Rothbard, J. 
B. The Design, Synthesis, and Evaluation of Molecules That Enable or Enhance Cellular 
Uptake: Peptoid Molecular Transporters. Proc. Natl. Acad. Sci. 2000, 97 (24), 13003–
13008. 
(7)  Acosta, J. J.; Muñoz, R. M.; González, L.; Subtil-Rodríguez, A.; Dominguez-Caceres, M. 
A.; García-Martínez, J. M.; Calcabrini, A.; Lazaro-Trueba, I.; Martín-Pérez, J. Src 
87 
Mediates Prolactin-Dependent Proliferation of T47D and MCF7 Cells via the Activation 
of Focal Adhesion kinase/Erk1/2 and Phosphatidylinositol 3-Kinase Pathways. Mol. 
Endocrinol. 2003, 17 (11), 2268–2282. 
(8)  García-Martínez, J. M.; Calcabrini, A.; González, L.; Martín-Forero, E.; Agulló-Ortuño, 
M. T.; Simon, V.; Watkin, H.; Anderson, S. M.; Roche, S.; Martín-Pérez, J. A Non-
Catalytic Function of the Src Family Tyrosine Kinases Controls Prolactin-Induced Jak2 
Signaling. Cell. Signal. 2010, 22 (3), 415–426. 
(9)  Moroco, J. A.; Baumgartner, M. P.; Rust, H. L.; Choi, H. G.; Hur, W.; Gray, N. S.; 
Camacho, C. J.; Smithgall, T. E. A Discovery Strategy for Selective Inhibitors of c-Src in 
Complex with the Focal Adhesion Kinase SH3/SH2-Binding Region. Chem. Biol. Drug 
Des. 2015, 86 (2), 144–155. 
(10)  Chou, T.-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-
Talalay Method. Cancer Res. 2010, 70 (2), 440–446. 
(11)  Warmuth, M.; Kim, S.; Gu, X.; Xia, G.; Adrián, F. Ba/F3 Cells and Their Use in Kinase 
Drug Discovery. Curr. Opin. Oncol. 2007, 19 (1), 55–60. 
(12)  Zhang, J.; Adrián, F. J.; Jahnke, W.; Cowan-Jacob, S. W.; Li, A. G.; Iacob, R. E.; Sim, T.; 
Powers, J.; Dierks, C.; Sun, F.; Guo, G.-R.; Ding, Q.; Okram, B.; Choi, Y.; 
Wojciechowski, A.; Deng, X.; Liu, G.; Fendrich, G.; Strauss, A.; Vajpai, N.; Grzesiek, S.; 
Tuntland, T.; Liu, Y.; Bursulaya, B.; Azam, M.; Manley, P. W.; Engen, J. R.; Daley, G. 
Q.; Warmuth, M.; Gray, N. S. Targeting Bcr-Abl by Combining Allosteric with ATP-
Binding-Site Inhibitors. Nature 2010, 463 (7280), 501–506. 
(13)  Kwarcinski, F. E.; Brandvold, K. R.; Phadke, S.; Beleh, O. M.; Johnson, T. K.; Meagher, 
J. L.; Seeliger, M. A.; Stuckey, J. A.; Soellner, M. B. Conformation-Selective Analogues 
of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity. ACS Chem. 
Biol. 2016, 11 (5), 1296–1304. 
(14)  O’Hare, T.; Eide, C. A.; Deininger, M. W. Bcr-Abl Kinase Domain Mutations and the 
Unsettled Problem of Bcr-AblT315I: Looking into the Future of Controlling Drug 
Resistance in Chronic Myeloid Leukemia. Clin. Lymphoma Myeloma Leuk. 2016, 7, 
S120–S130. 
(15)  Prasad, V.; Mailankody, S. The Accelerated Approval of Oncologic Drugs: Lessons from 
Ponatinib. JAMA 2014, 311 (4), 353–354. 
(16)  Wylie, A.; Schoepfer, J.; Berellini, G.; Cai, H.; Caravatti, G.; Cotesta, S.; Dodd, S.; 
Donovan, J.; Erb, B.; Furet, P.; Gangal, G.; Grotzfeld, R.; Hassan, Q.; Hood, T.; Iyer, V.; 
Jacob, S.; Jahnke, W.; Lombardo, F.; Loo, A.; Manley, P. W.; Marzinzik, A.; Palmer, M.; 
Pelle, X.; Salem, B.; Sharma, S.; Thohan, S.; Zhu, S.; Keen, N.; Petruzzelli, L.; Vanasse, 
K. G.; Sellers, W. R. ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents 
Emergence of Resistant Disease When Administered in Combination with Nilotinib in an 
in Vivo Murine Model of Chronic Myeloid Leukemia. Blood 2014, 124 (21), 398. 
(17)  Furet, P.; Grotzfeld, R. M.; Jones, D. B.; Manley, P.; Marzinzik, A.; Pelle, X. F. A.; 
Salem, B.; Schoepfer, J. Preparation of Benzamide Derivatives for Inhibiting the Activity 
of ABL1, ABL2 and BCR-ABL1 for Treating Cancer and Viral Infections. WO 
2013/171642 A1, 2013. 
(18)  Chou, T.-C. Theoretical Basis , Experimental Design , and Computerized Simulation of 













Figure A.1:  Crystal structures showing measurements between the ATP-pocket and SH2 domain of 
protein tyrosine kinases in various conformations. A) Closed/inactive conformation (1.5 Å, PDB 
code: 2SRC)  B) Open/active conformations exhibiting a variety of distances between the kinase 





Figure A.2: PyMOL measurement in Angstroms of the PEG linker used to create 2.2 and bivalent inhibitors 
2.3, 2.4, and 2.5. 
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Avg IC50 < 10 nM 
[ATP] = 5 mM 





Avg IC50 < 10 nM 
[ATP] = 5 mM 
[Src] = 10 nM 
 
Analytical Data for IC50 Values against 3D c-Src. 
2.1: 
  









Avg IC50 < 10 nM 
[ATP] = 5 mM 




Avg IC50 < 10 nM 
[ATP] = 5 mM 




Avg IC50 < 10 nM 
[ATP] = 5 mM 





Avg EC50 (activation) = 1.6 ± 0.3 μM 
 





















Avg IC50 = 2.8 ± 0.7 μM 
 









Avg IC50 = 189 ± 8 nM 
 




















Avg IC50 = 1.8 ± 0.1 μM 
 










IC50 = 9.3 μM 
 
Avg IC50 = 5.3 ± 0.6 μM 
Blk 
 
IC50 = 21.8 μM 
 
Avg IC50 = 5.3 ± 0.7 μM 
Frk 
 
IC50 = 9.6 μM 
 




IC50 = 2.8 μM 
 
Avg IC50 = 0.27 ± 0.02 μM 
Fgr 
 
IC50 =4.6 μM 
 
Avg IC50 = 3.1 ± 1.9 μM 
Lyn 
 
IC50 = 10.8 μM 
 












Avg IC50 = 2.2 ± 0.8 μM 
 
Analytical Data for IC50 Values against 3D SH2-enagaged Hck. 
2.1: 
  






Avg IC50 = 10 ± 3 μM 
 




















Avg IC50 = 6.1 ± 0.7 μM 
 









Avg IC50 = 4.1 ± 0.4 μM 
 
Analytical Data for EC50 Value of SH2 Peptide 2.21.  
3D Src 
Avg EC50 = 0.73 ± 0.1 μM 
 
3D Hck 










IC50 = 18 ± 5 nM 
2.4: 
  





Analytical Data for Chapter III  
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Plates 3, 8, 12 had no hits 
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Analytical data for Protein Half Lives as Determined via 5 Time Point Proteolysis Assay 
 
 5-Point Half Life (min) 
Apo c-Src  




























































































































































Analytical data for Protein Half Lives as Determined via 10 Time Point Proteolysis Assay 
 
 10-Point Half Life (min) 
Apo c-Src  








































Avg EC50 (activation) = 84 ± 21 μM  
[ATP] = 100 μM 
 
Avg EC50 (activation) =  83 μM  
[ATP] = 1 mM 
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Avg IC50 = 930 ± 70 μM 
 












Avg IC50 = 550 ± 100 μM 
 








Analytical data for EC50 value of SH2 Peptide 2.21.  
2.21 
 
EC50 = 100 ± 7 nM 
2.21 + 100 μM 1-E8 
 








GI50 > 10 μM 
Das-DFGO-II 
 
Avg GI50 = 157 ± 44 nM 
Das-DFGO-II + 10 μM 1-E8 
 




Analytical Data for Chapter IV 
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Analytical data for IC50 Values against c-Abl kinase domain.  
4.1: 
  




Avg IC50 = 26 ± 1 nM 
127 
4.2 + 8 μM GNF-2 
 
Avg IC50 = 1.1 ± 0.4 μM 
4.3: 
  
Avg IC50 = 149 ± 47 nM 
 
Analytical data for IC50 Values against A337N c-Abl kinase domain.  
4.1: 
  
Avg IC50 > 250 μM 
4.2: 
  




Avg IC50 = 270 ± 59 nM 
 




Avg IC50 = 700 ± 400 μM 
4.2: 
  
Avg IC50 = 900 ± 400 nM 
4.3: 
  











Avg IC50 = 440 ± 50 μM 
4.2: 
  
Avg IC50 = 700 ± 170 nM 
4.3: 
  
Avg IC50 = 230 ± 90 nM 
 








Avg IC50 < 30 nM 
4.3: 
  
Avg IC50 = 418 ± 23 nM 
 












Avg IC50 = 290 ± 40 nM 
 




Avg IC50 = 110 ± 30 μM 
4.2: 
  












Avg IC50 = 120 ± 13 μM 
4.2: 
  
Avg IC50 = 160 ± 40 nM 
4.3: 
  
Avg IC50 = 170 ± 60 nM 
 
Analytical data for IC50 Values against c-Src kinase domain. 
4.2: 
  
Avg IC50 = 1.2 ± 0.4 μM 
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4.2 + 8 μM GNF-2 
 





Avg IC50 = 360 ± 90 nM 
 
Analytical Data for IC50 Values against Abl Using Kinase Seeker, Luceome 
Biotechnologies. 




IC50 = 0.0027 ± 0.0003 μM 
 




IC50 = 0.0118 ± 0.0014 μM 
 
IC50 = 0.0012 ± 0.0005 μM 
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Dasatinib + 20 μM GNF-2  
 
IC50 = 0.0050 ± 0.0010 μM 
4.2 + 20 μM GNF-2  
 





IC50 = 0.032 ± 0.002 μM 
 


















Avg GI50 = 713 nM 
 
Avg GI50 > 10 μM 
 









Analytical Data for Chapter V 
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Equation for Determination of Combination Index (CI) 
 
 CI =  
    
     
 
    
     
 = 
    
      
  
       
  
    
 
    
      
  
       
  





where (D)1 and (D)2 are the doses of drugs 1 and 2, Dm is the dose required to produce the 
median effect (analogous to IC50, ED50, or LD50 values), m is a Hill-type coefficient signifying 




Analytical Data for IC50 Values against 3D c-Abl 
Imatinib 
Avg IC50 = 270 ± 50 nM 
Avg Ki = 5.4 ± 0.9 nM 
 
GNF-2 
IC50 = 114.7 nM 







Analytical data for IC50 Values against 3D T315I Abl. 
GNF-2 
Avg IC50 > 83 μM 
Avg Ki > 42 μM 
[ATP] = 100 μM 
[Abl] = 60 nM 
 
Das-CHO-II 
Avg IC50 = 141 ± 100 μM 
Avg Ki = 70 ± 50 μM 
[ATP] = 100 μM 
[Abl] = 60 nM 
 
 
Analytical data for IC50 Values against 3D P112S Abl.  
GNF-2 
Avg IC50 > 83 μM 
Avg Ki > 42 μM 
[ATP] = 100 μM 




Avg IC50 < 60 nM 
Ki < 1.2 nM 
 [Abl] = 60 nM 
 
Imatinib 
Avg IC50 = 113 ± 27 nM 
Avg Ki = 2.2 ± 0.5 nM 
 
 
Analytical data for IC50 Values against 3D S229P Abl.  
GNF-2 
Avg IC50 > 83 μM 
Avg Ki > 42 μM 
[ATP] = 100 μM 




Avg IC50 < 30 nM 
Avg Ki < 0.6 nM 
 
Imatinib 
Avg IC50 < 30 nM 
Avg Ki < 0.6 nM 
 
 
Analytical data for BODIPY probe EC50 determination.  
 
  EC50 (nM) 
 Without GNF-2 With 1 μM GNF-2 
Das-DFGO-II 
 
Avg EC50 = 3.4 ± 0.4 
 




Avg EC50 = 21 ± 1 
 
Avg EC50 = 5.2 ± 1.1 
 
 
Analytical data for Protein Half Lives as Determined via Proteolysis Assay.  
 
 Half Life (min) 
T1/2 
WT Abl T1/2 
 
log(Relative Half Life) 
WT Abl (n = 5) 21.2 ± 3.3 1 0 
SH3 Engaged Abl 202.0 9.53 0.979 
A337N Abl 9.8 0.46 -0.337 
WT Abl + Dasatinib 2.9 0.14 -0.854 
WT Abl + Imatinib 2.2 0.10 -1 
WT Abl + Nilotinib 1.3 0.06 -1.222 
WT Abl + Ponatinib 2.2 0.10 -1 
WT Abl + Das-DFGO-II 2.1 0.10 -1 
WT Abl + Das-CHO-II 37.7 1.78 0.250 
WT Abl + GNF-2 154.6 7.29 0.863 
WT Abl + Dasatinib & GNF-2 35.0 1.65 0.217 
WT Abl + Das-DFGO-II & GNF-2 16.5 0.78 -0.108 
WT Abl + Das-CHO-II & GNF-2 279.4 13.18 1.120 
WT Abl + "ABL001" 83.2 3.92 0.593 
T315I Abl 2.5 0.12 -0.921 
T315I Abl + GNF-2 16.1 0.76 -0.119 
T315I Abl + Das-CHO-II 3.7 0.17 -0.770 
T315I Abl + GNF-2 & Das-CHO-II 44.9 2.12 0.326 
P112S Abl 3.7 0.17 -0.770 
P112S Abl + GNF-2 16.4 0.77 -0.114 
P112S Abl + Das-CHO-II 4.0 0.19 -0.721 
S229P Abl 10.0 0.47 -0.328 
S229P Abl + GNF-2 48.1 2.27 0.356 

















WT Abl + Dasatinib 
 
 
WT Abl + Imatinib 
 
 
WT Abl + Nilotinib 
 
 
WT Abl + Ponatinib 
 
 
WT Abl + Das-DFGO-II 
 
 




WT Abl + GNF-2 
 
 
WT Abl + Dasatinib & GNF-2 
 
 
WT Abl + Das-DFGO-II & GNF-2 
 
 
WT Abl + Das-CHO-II & GNF-2 
 
 








T315I Abl + GNF-2 
 
 
T315I Abl + Das-CHO-II 
 
 








P112S Abl + GNF-2 
 
 









S229P Abl + GNF-2 
 
 
S229P Abl + Das-CHO-II 
 
Analytical data for GI50 Values in BCR-Abl Ba/F3 cells.  
Das-CHO-II 
GI50 = 546.0 nM 
 
GNF-2 
GI50 = 452.3 nM 
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Das-CHO-II + 200 nM GNF-2 
GI50 = 0.545 nM 
 
GNF-2 + 100 nM Das-CHO-II 
GI50 = 17.2 nM 
 
 
Analytical data for GI50 Values in T315I Abl Ba/F3 cells.  
Das-CHO-II 




GI50 > 10 μM 
 
Das-CHO-II + 2 μM GNF-2 
GI50 = 127.9 nM 
 
GNF-2 + 2 μM Das-CHO-II 





Analytical data for GI50 Values in Parental Ba/F3 cells.  
Das-CHO-II 
GI50 = 2.8 μM 
 
GNF-2 
GI50 > 10 μM 
 
Das-CHO-II + 200 nM GNF-2 
GI50 = 1.5 μM 
 
151 
GNF-2 + 100 nM Das-CHO-II 
GI50 > 5 μM 
 
 
Analytical data for GI50 Values in K562 cells.  
Das-CHO-II 
GI50 = 64.4 nM 
 
GNF-2 
GI50 = 807.7 nM 
 
152 
Das-CHO-II + 800 nM GNF-2 
GI50 = 16.5 nM 
 
GNF-2 + 65 nM Das-CHO-II 
GI50 = 215.3 nM 
 
 
Analytical Data for Cellular Synergy.  
 
Cell Line Combinations CI50 CI75 CI90 CI95 
WT Abl Ba/F3 
Dasatinib + GNF-2 0.84 0.93 1.04 1.12 
Imatinib + GNF-2 0.88 0.87 0.87 0.87 
Nilotinib + GNF-2 0.94 0.94 0.94 0.94 
Ponatinib + GNF-2 1.02 1.02 1.02 1.02 
Das-DFGO-II + GNF-2 0.74 0.70 0.66 0.64 
Das-CHO-II + GNF-2 0.23 0.23 0.23 0.23 
Das-CHO-II + "ABL001" 0.66 0.66 0.66 0.66 
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